Wellness Center USA (WCUI) 10-K 15 Jan 19 2018 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Sep. 30, 2018	Mar. 31, 2018
Document And Entity Information
Entity Registrant Name	Wellness Center USA, Inc.
Entity Central Index Key	1,516,887
Document Type	10-K
Document Period End Date	Sep. 30, 2018
Amendment Flag	false
Current Fiscal Year End Date	--09-30
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business Flag	true
Entity Emerging Growth Company	false
Entity Ex Transition Period	false
Entity Shell Company	false
Entity Public Float		$ 10,313,724
Entity Common Stock, Shares Outstanding	100,952,569
Trading Symbol	WCUI
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2,018

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Sep. 30, 2018	Sep. 30, 2017
Current Assets
Cash	$ 4,210	$ 29,369
Accounts receivable		24,999
Inventories		12,335
Prepaid expenses and other current assets	1,550	1,751
Total Current Assets	5,760	68,454
Property and equipment, net	2,619	5,126
Other assets	16,760	16,760
Total Other Assets	19,379	21,886
TOTAL ASSETS	25,139	90,340
Current Liabilities
Accounts payable and accrued expenses	572,753	203,367
Accrued payroll - officers		13,440
Deferred revenue	8,624	55,098
Convertible notes payable	202,922	49,884
Loans payable from officers and shareholders	66,000	59,000
Total Current Liabilities	850,299	380,789
Shareholders' Deficit
Common stock, par value $0.001, 185,000,000 shares authorized; 100,952,569 and 90,284,916 shares issued and outstanding, respectively	100,952	90,285
Additional paid-in capital	22,450,252	19,069,211
Accumulated deficit	(22,974,740)	(19,132,557)
Total Wellness Center USA shareholders' equity (deficit)	(423,536)	26,939
Non-controlling interest	(401,624)	(317,388)
Total Shareholder's deficit	(825,160)	(290,449)
TOTAL LIABILITIES AND SHAREHOLDERS' DEFICIT	$ 25,139	$ 90,340

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2016
Statement of Financial Position [Abstract]
Common stock, par value	$ 0.001	$ 0.001	$ 0.001
Common stock, shares authorized	185,000,000	185,000,000	75,000,000
Common stock, shares, issued	100,952,569	90,284,916
Common stock, shares, outstanding	100,952,569	90,284,916

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($)	12 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
Sales:
Total Sales	$ 213,723	$ 272,724
Cost of goods sold	79,960	146,944
Gross profit	133,763	125,780
Operating expenses	2,226,362	2,129,184
Loss from operations	(2,092,599)	(2,003,404)
Other income (expenses)
Amortization of debt discount	(318,038)	(49,884)
Gain on extinguishment of debt		288,777
Loss on modification of conversion price on convertible note payable	(158,400)
Loss on modification of exercise price on warrants in connection with convertible note payable	(5,445)
Financing costs	(891,583)	(51,150)
Interest expense	(27,354)	(2,351)
Total other income (expenses)	(1,400,820)	185,392
LOSS FROM CONTINUING OPERATIONS	(3,493,419)	(1,818,012)
DISCONTINUED OPERATIONS
Loss from discontinued operations		(147,476)
Gain from sale of discontinued operations		252,508
Income (loss) from discontinued operations		105,032
NET LOSS	(3,493,419)	(1,712,980)
Net loss attributable to non-controlling interest	84,236	122,250
NET LOSS ATTRIBUTABLE TO WELLNESS CENTER USA, INC.	(3,409,183)	(1,590,730)
Deemed dividend relating to settlement with shareholder	(433,000)
NET LOSS ATTRIBUTABLE TO COMMON SHAREHOLDERS	$ (3,842,183)	$ (1,590,730)
BASIC AND DILUTED LOSS PER SHARE
Loss per share from continuing operations	$ (0.04)	$ (0.02)
Income (loss) per share from discontinued operations		0
Net loss per share	$ (0.04)	$ (0.02)
WEIGHTED-AVERAGE COMMON SHARES OUTSTANDING BASIC AND DILUTED	94,475,383	86,002,821
Trade [Member]
Sales:
Total Sales	$ 140,023	$ 209,599
DISCONTINUED OPERATIONS
NET LOSS	1
Consulting Services [Member]
Sales:
Total Sales	$ 73,700	$ 63,125

Consolidated Statement of Share

Consolidated Statement of Shareholders' Deficit - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	Shares to be Issued [Member]	Accumulated Deficit [Member]	Total WCUI Deficit [Member]	Non-controlling Interest [Member]	Total
Balance at Sep. 30, 2016	$ 74,969	$ 16,464,896	$ 442,440	$ (17,541,827)	$ (559,562)	$ (195,138)	$ (754,700)
Balance, shares at Sep. 30, 2016	74,968,352		5,048,650
Issuance of common stock issuable	$ 5,048	437,352	$ (442,400)
Issuance of common stock issuable, shares	5,048,650		(5,048,650)
Common stock issued for cash	$ 5,837	878,763			884,600		884,600
Common stock issued for cash, shares	5,837,500
Exercise of stock warrants	$ 4,066	622,556			626,622		$ 626,622
Exercise of stock warrants, shares	4,065,414
Retirement of common stock in legal settlement	$ (250)	250
Retirement of common stock in legal settlement, shares	(250,000)
Fair value of vested stock options		326,359			326,359		326,359
Fair value of common stock issued for services	$ 450	138,050			138,500		138,500
Fair value of common stock issued for services, shares	450,000
Fair value of common stock issued in connection with convertible note payable	$ 165	50,985			51,150		51,150
Fair value of common stock issued in connection with convertible note payable, shares	165,000
Discount on convertible note payable due to beneficial conversion and warrants		150,000			150,000		150,000
Discount on convertible note payable due to beneficial conversion and warrants, shares
Fair value of additional shares issued upon conversion of loans payable from officers and shareholders
Net loss				(1,590,730)	(1,590,730)	(122,250)	(1,712,980)
Balance at Sep. 30, 2017	$ 90,285	19,069,211		(19,132,557)	26,939	(317,388)	(290,449)
Balance, shares at Sep. 30, 2017	90,284,916
Common stock issued for cash	$ 1,614	175,386			177,000		177,000
Common stock issued for cash, shares	1,614,286
Exercise of stock warrants	$ 1,407	169,507			170,914		$ 170,914
Exercise of stock warrants, shares	1,407,619
Fair value of vested stock options		612,503			612,503		$ 612,503
Fair value of common stock issued for services	$ 770	110,530			111,300		111,300
Fair value of common stock issued for services, shares	770,000
Fair value of common stock issued in connection with convertible note payable	$ 748	113,591			114,339		114,339
Fair value of common stock issued in connection with convertible note payable, shares	747,751
Discount on convertible note payable due to beneficial conversion and warrants		250,000			250,000		250,000
Discount on convertible note payable due to beneficial conversion and warrants, shares
Shares issued upon conversions of note payable	$ 1,746	172,817			174,563		174,563
Shares issued upon conversions of note payable, shares	1,745,631
Shares issued upon conversion of loans payable from officers and shareholders	$ 3,019	403,981			407,000		407,000
Shares issued upon conversion of loans payable from officers and shareholders, shares	2,800,713
Fair value of additional shares issued upon conversion of loans payable from officers and shareholders		30,583			30,583		30,583
Fair value of additional shares issued upon conversion of loans payable from officers and shareholders, shares	218,452
Fair value of warrants issued as an inducement for conversion of loans payable from officers and shareholders		689,934			689,934		689,934
Fair value of warrants issued as an inducement for conversion of loans payable from officers and shareholders, shares
Fair value of shares and warrants issued upon settlement of Favored Nation clause	$ 1,067	431,933		(433,000)
Fair value of shares and warrants issued upon settlement of Favored Nation clause, shares	1,066,667
Fair value of shares and warrants issued to a stockholder upon settlement	$ 296	56,431			56,727		56,727
Fair value of shares and warrants issued to a stockholder upon settlement, shares	296,534
Loss on modification of conversion price and exercise price on warrants in connection with convertible note payable		163,845			163,845		163,845
Net loss				(3,409,183)	(3,409,183)	(84,236)	(3,493,419)
Balance at Sep. 30, 2018	$ 100,952	$ 22,450,252		$ (22,974,740)	$ (423,536)	$ (401,624)	$ (825,160)
Balance, shares at Sep. 30, 2018	100,952,569

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
Cash Flows from Operating Activities
Net loss	$ (3,493,419)	$ (1,712,980)
Adjustments to reconcile net loss to net cash used in operating activities from continuing operations:
Gain from sale of discontinued operations		(252,508)
Loss from discontinued operations		105,032
Depreciation expense	2,507	11,125
Amortization of debt discount	318,038	49,884
Gain on extinguishment of debt		(288,777)
Fair value of common shares issued for services	111,300	138,500
Fair value of common stock issued in connection with convertible note payable	114,339	51,150
Fair value of stock options and warrants issued for services	612,503	326,359
Fair value of additional shares issued upon conversion of loans payable from officers and shareholders	30,583
Fair value of warrants issued upon conversion of loans payable from officers and shareholders	689,934
Loss on modification of conversion price on convertible note payable	158,400
Loss on modification of exercise price on warrants in connection with convertible note payable	5,445
Fair value of common stock issued in connection with convertible note payable	114,339
Fair value of additional shares and warrants issued to a stockholder	56,727
(Increase) Decrease in:
Accounts receivable	24,999	(24,999)
Inventories	12,335	66,834
Prepaid expenses and other current assets	201	24,883
(Decrease) Increase in:
Accounts payable and accrued expenses	378,948	(102,959)
Accrued payroll taxes		(37,436)
Accrued payroll - officers	(13,440)	(8,451)
Deferred revenue	(46,473)	(22,277)
Net cash used in operating activities from continuing operations	(1,037,073)	(1,634,176)
Net cash used in operating activities from discontinued operations		(112,466)
Net cash used in operating activities	(1,037,073)	(1,746,642)
Cash Flows from Investing Activities
Purchases of property and equipment		(1,945)
Net cash used in investing activities from continuing operations		(1,945)
Net cash used in investing activities from discontinued operations		(1,704)
Net cash used in investing activities		(3,649)
Cash Flows from Financing Activities
Proceeds from loans payable from officers and shareholders	434,500	50,000
Repayment of loans payable from officers and shareholders	(20,500)
Proceeds from convertible note payable	250,000	150,000
Repayment of advances from related party		(13,041)
Common stock issued for cash	177,000	884,600
Exercise of stock options and warrants	170,914	626,622
Net cash provided by financing activities	1,011,914	1,698,181
Net decrease in cash	(25,159)	(52,110)
Cash beginning of period	29,369	81,749
Cash end of period	4,210	29,369
Supplemental cash flows disclosures:
Interest paid
Taxes paid
Supplemental non-cash financing disclosures:
Debt discount on convertible note payable	250,000	150,000
Conversion of convertible note payable and accrued interest into common shares	174,563
Conversion of loans payable from officers and shareholders into common shares	407,000
Non-controlling interest's share in losses of a subsidiary	84,236	122,250
Conversion of accrued interest into common shares	$ 9,563

Basis of Presentation

Basis of Presentation	12 Months Ended
	Sep. 30, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	NOTE 1 – BASIS OF PRESENTATION Organization and Operations Wellness Center USA, Inc. (“WCUI” or the “Company”) was incorporated in June 2010 under the laws of the State of Nevada. The Company initially engaged in online sports and nutrition supplements marketing and distribution. The Company subsequently expanded into additional businesses within the healthcare and medical sectors through acquisitions, including Psoria-Shield Inc. (“PSI”), National Pain Centers, Inc. (“NPC”), and StealthCo Inc. (“SCI”), d/b/a Stealth Mark, Inc. On August 11, 2017, the Company entered into an agreement to sell 100% of the issued and outstanding shares of NPC, which has been accounted for as a discontinued operation on the consolidated statement of operations for the year ended September 30, 2017. See Note 3 for details relating to the sale. The Company currently operates in the following business segments: (i) distribution of targeted Ultra Violet (“UV”) phototherapy devices for dermatology; and (ii) authentication and encryption products and services. The segments are operated, respectively, through PSI and SCI. Going Concern The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. As reflected in the accompanying consolidated financial statements, the Company has not yet generated significant revenues and has incurred recurring net losses. During the year ended September 30, 2018, the Company incurred a loss from continuing operations of $3,493,419 and used cash in operations from continuing operations of $1,037,073, and had a shareholders’ deficit of $825,160 as of September 30, 2018. These factors raise substantial doubt about the Company’s ability to continue as a going concern. The ability of the Company to continue as a going concern is dependent upon the Company’s ability to raise additional funds and implement its strategies. The financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern. At September 30, 2018, the Company had cash on hand in the amount of $4,210. The ability to continue as a going concern is dependent on the Company attaining and maintaining profitable operations in the future and raising additional capital soon to meet its obligations and repay its liabilities arising from normal business operations when they come due. Since inception, we have funded our operations primarily through equity and debt financings and we expect to continue to rely on these sources of capital in the future. During the year ended September 30, 2018, the Company received $1,032,414 through the sale of its common stock, the exercise of stock warrants and from debt offerings. No assurance can be given that any future financing will be available or, if available, that it will be on terms that are satisfactory to the Company. Even if the Company is able to obtain additional financing, it may contain undue restrictions on our operations, in the case of debt financing, or cause substantial dilution for our stock holders, in case of equity financing.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Sep. 30, 2018
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Consolidation The Company’s consolidated subsidiaries and/or entities are as follows: Name of consolidated subsidiary or entity State or other jurisdiction of incorporation or organization Date of incorporation or formation (date of acquisition/disposition, if applicable) Attributable interest Psoria-Shield Inc. (“PSI”) The State of Florida June 17, 2009 (August 24, 2012) 100% StealthCo, Inc. (“StealthCo”) The State of Illinois March 18, 2014 100% Psoria Development Company LLC. (“PDC”) The State of Illinois January 15, 2015 50% Use of Estimates The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the U.S requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the financial statement date, and reported amounts of revenue and expenses during the reporting period. Significant estimates are used in the valuation of accounts receivable and allowance for uncollectible amounts, inventory and obsolescence reserves, accruals for potential liabilities, valuations of stock-based compensation, realization of deferred tax assets, among others. Actual results could differ from these estimates. Income (Loss) Per Share Basic loss per share is computed by dividing net loss applicable to common shareholders by the weighted average number of outstanding common shares during the period. Diluted loss per share is computed by dividing the net loss applicable to common shareholders by the weighted average number of common shares outstanding plus the number of additional common shares that would have been outstanding if all dilutive potential common shares had been issued. For the years ended September 30, 2018 and 2017, the basic and diluted shares outstanding were the same, as potentially dilutive shares were considered anti-dilutive. At September 30, 2018 and 2017, the dilutive impact of outstanding stock options for 17,946,667 and 6,822,500 shares, respectively, and outstanding warrants for 67,907,728 and 64,161,304 shares, respectively, have been excluded because their impact on the loss per share is anti-dilutive. Revenue Recognition The Company recognizes revenue when it is realized or realizable and earned. The Company considers revenue realized or realizable and earned when all of the following criteria are met: (i) persuasive evidence of an arrangement exists, (ii) the product has been shipped or the services have been rendered to the customer, (iii) the sales price is fixed or determinable, and (iv) collectability is reasonably assured. In addition to the aforementioned general policy, the following are the specific revenue recognition policies for each major category of revenue: (i) Sale of products : (ii) Consulting services: Payments received before the relevant criteria for revenue recognition are satisfied are recorded as deferred revenue. Deferred revenue at September 30, 2018 and 2017 was $8,624 and $55,098, respectively. Accounts Receivable The Company evaluates the collectability of its trade accounts receivable based on a number of factors. In circumstances where the Company becomes aware of a specific customer’s inability to meet its financial obligations to the Company, a specific reserve for bad debts is estimated and recorded, which reduces the recognized receivable to the estimated amount the Company believes will ultimately be collected. In addition to specific customer identification of potential bad debts, bad debt charges are recorded based on the Company’s historical losses and an overall assessment of past due trade accounts receivable outstanding. The allowance for doubtful accounts and returns is established through a provision reducing the carrying value of receivables. At September 30, 2018 and 2017, no allowance for doubtful accounts and returns was considered necessary. Inventories Inventories are stated at the lower of cost or market. Cost is computed on a first-in, first-out basis. At September 30, 2017, primarily all of the inventories totaling to $12,335 consisted of finished goods. At September 30, 2018, the Company’s net inventories had no value. The Company provides inventory reserves based on excess and obsolete inventories determined primarily by future demand forecasts. The write down amount is measured as the difference between the cost of the inventory and market based upon assumptions about future demand and charged to the provision for inventory, which is a component of cost of sales. At the point of the loss recognition, a new, lower cost basis for that inventory is established, and subsequent changes in facts and circumstances do not result in the restoration or increase in that newly established cost basis. During the year ended September 30, 2018, the Company provided a reserve of $12,335 that is included in cost of goods sold to account for its estimate of slow moving and obsolete inventory. Property and Equipment Property and equipment are carried at cost less accumulated depreciation and amortization. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets. The Company has determined the estimated useful lives of its property and equipment, as follows: Computer equipment 5 years Medical equipment 5 years Furniture and fixtures 7 years Vehicles 3 years Software 3 years Maintenance and repairs are charged to expense as incurred. The cost and accumulated depreciation of assets sold or otherwise disposed of are removed from the related accounts and the resulting gain or loss is reflected in the statements of operations. Management assesses the carrying value of property and equipment whenever events or changes in circumstances indicate that the carrying value may not be recoverable. If there is indication of impairment, management prepares an estimate of future cash flows expected to result from the use of the asset and its eventual disposition. If these cash flows are less than the carrying amount of the asset, an impairment loss is recognized to write down the asset to its estimated fair value. Income Taxes Income tax expense is based on pretax financial accounting income. Deferred tax assets and liabilities are recognized for the expected tax consequences of temporary differences between the tax bases of assets and liabilities and their reported amounts. Valuation allowances are recorded to reduce deferred tax assets to the amount that will more likely than not be realized. The Company recorded a valuation allowance against its deferred tax assets as of September 30, 2018 and 2017. The Company accounts for uncertainty in income taxes using a two-step approach to recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount that is more than 50 percent likely of being realized upon settlement. The Company classifies the liability for unrecognized tax benefits as current to the extent that the Company anticipates payment (or receipt) of cash within one year. Interest and penalties related to uncertain tax positions are recognized in the provision for income taxes. Fair Value measurements The Company determines the fair value of its assets and liabilities based on the exchange price in U.S. dollars that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value maximize the use of observable inputs and minimize the use of unobservable inputs. The Company uses a fair value hierarchy with three levels of inputs, of which the first two are considered observable and the last unobservable, to measure fair value: ● Level 1 — ● Level 2 — ● Level 3 — The carrying amounts of financial instruments such as cash, accounts receivable, inventories, and accounts payable and accrued liabilities, approximate the related fair values due to the short-term maturities of these instruments. Non-controlling Interest Non-controlling interest represents the non-controlling interest holder’s proportionate share of the equity of the Company’s majority-owned subsidiary, PDC. Non-controlling interest is adjusted for the non-controlling interest holder’s proportionate share of the earnings or losses and other comprehensive income (loss), if any, and the non-controlling interest continues to be attributed its share of losses even if that attribution results in a deficit non-controlling interest balance. Stock-Based Compensation The Company periodically grants stock options and warrants to employees and non-employees in non-capital raising transactions as compensation for services rendered. The Company accounts for stock option and stock warrant grants to employees based on the authoritative guidance provided by the Financial Accounting Standards Board where the value of the award is measured on the date of grant and recognized over the vesting period. The Company accounts for stock option and stock warrant grants to non-employees in accordance with the authoritative guidance of the Financial Accounting Standards Board where the value of the stock compensation is determined based upon the measurement date at either a) the date at which a performance commitment is reached, or b) at the date at which the necessary performance to earn the equity instruments is complete. Non-employee stock-based compensation charges generally are amortized over the vesting period on a straight-line basis. In certain circumstances where there are no future performance requirements by the non-employee, option or warrant grants are immediately vested and the total stock-based compensation charge is recorded in the period of the measurement date. The fair value of the Company’s common stock option and warrant grants are estimated using a Black-Scholes Merton option pricing model, which uses certain assumptions related to risk-free interest rates, expected volatility, expected life of the common stock options, estimated forfeitures and future dividends. Compensation expense is recorded based upon the value derived from the Black-Scholes option pricing model, and based on actual experience. The assumptions used in the Black-Scholes Merton option pricing model could materially affect compensation expense recorded in future periods. Recently Issued Accounting Pronouncements In May 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2014-09, Revenue from Contracts with Customers. ASU 2014-09 is a comprehensive revenue recognition standard that will supersede nearly all existing revenue recognition guidance under current U.S. GAAP and replace it with a principle-based approach for determining revenue recognition. ASU 2014-09 will require that companies recognize revenue based on the value of transferred goods or services as they occur in the contract. The ASU also will require additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to obtain or fulfill a contract. ASU 2014-09 is effective for interim and annual periods beginning after December 15, 2017. Early adoption is permitted only in annual reporting periods beginning after December 15, 2016, including interim periods therein. Entities will be able to transition to the standard either retrospectively or as a cumulative-effect adjustment as of the date of adoption. The Company is in the process of evaluating the impact of ASU 2014-09 on the Company’s financial statements and disclosures but does not believe the adoption of this standard will have a material effect on the Company, if any. In February 2016, the FASB issued Accounting Standards Update (ASU) No. 2016-02, Leases. ASU 2016-02 requires a lessee to record a right of use asset and a corresponding lease liability on the balance sheet for all leases with terms longer than 12 months. ASU 2016-02 is effective for all interim and annual reporting periods beginning after December 15, 2018. Early adoption is permitted. A modified retrospective transition approach is required for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. The Company is in the process of evaluating the impact of ASU 2016-02 on the Company’s financial statements and disclosures. Other recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the Securities and Exchange Commission did not or are not believed by management to have a material impact on the Company’s present or future consolidated financial statements.

Discontinued Operations

Discontinued Operations	12 Months Ended
	Sep. 30, 2018
Discontinued Operations and Disposal Groups [Abstract]
Discontinued Operations	NOTE 3 – DISCONTINUED OPERATIONS On August 11, 2017, the Company entered into an agreement with Dr. Jay Joshi to sell 100% of the issued and outstanding shares of NPC Inc. (“NPC”) to Dr. Joshi. As part of the agreement, Dr. Joshi and NPC released the Company from any and all liabilities, claims and obligations of the Company in favor of Dr. Joshi or NPC and arising from or relating to the operation of the NPC business. Also, as part of the agreement, Dr. Joshi’s employment agreement with NPC was terminated and all assets and liabilities of NPC were transferred to Dr. Joshi as of the date of the agreement, including $365,459 of accrued compensation and shareholder advances owed to Dr. Joshi by NPC. The Company agreed to sell NPC to Dr. Joshi so that it could focus on its other business segments, PSI and Stealth Mark, which are technology companies, while NPC was a service business. As part of the agreement, the Company agreed to issue Dr. Joshi stock options to purchase 500,000 shares of its common stock with an exercise price of $0.25 per share with a fair value of $106,350. Dr. Joshi continued to serve on the Company’s board of directors until February 5, 2018. During the year ended September 30, 2017, the Company recorded a $252,508 gain relating to this transaction. Year Ended September 30, 2017 Total Sales $ 83,826 Operating expenses 231,302 Loss from discontinued operations $ (147,476 ) Other income Gain from sale of discontinued operations $ 252,508

Property and Equipment

Property and Equipment	12 Months Ended
	Sep. 30, 2018
Property, Plant and Equipment [Abstract]
Property and Equipment	NOTE 4 - PROPERTY AND EQUIPMENT Property and equipment consisted of the following at September 30, 2018 and 2017: September 30, 2018 September 30, 2017 Vehicles $ 15,000 $ 15,000 Computer equipment 10,456 10,456 Furniture and fixtures 23,998 23,998 Medical equipment 18,889 18,889 Software 23,207 23,207 Leasehold improvements 15,170 15,170 106,720 106,720 Less: accumulated depreciation and amortization (104,101 ) (101,594 ) Property and equipment, net $ 2,619 $ 5,126 Depreciation expense for the years ended September 30, 2018 and 2017 was $2,507 and $11,125, respectively.

Loans Payable from Officers and

Loans Payable from Officers and Shareholders	12 Months Ended
	Sep. 30, 2018
Debt Disclosure [Abstract]
Loans Payable from Officers and Shareholders	NOTE 5 – LOANS PAYABLE FROM OFFICERS AND SHAREHOLDERS As of September 30, 2016, loans payable from officers and shareholders of $9,000 were outstanding. During the year ended September 30, 2017, the Company borrowed $20,000 and $30,000 from two separate shareholders. The short-term loans are unsecured, have no stated interest rate and are due on demand. As of September 30, 2017, loans payable to shareholders of $59,000 were outstanding. During the year ended September 30, 2018, the Company borrowed $434,500 under 22 short-term, unsecured loans. The loans have an interest rate of eight percent and are due one year from the date of issuance. During the year ended September 30, 2018, the Company repaid $20,500 of the loans payable and $407,000 were converted into 2,800,713 shares of the Company’s common stock. In connection with the conversion of the loans payable, the Company issued warrants to purchase 6,038,336 shares of common stock to the holders as an inducement to convert. The warrants expire five years from the date of grant and have exercise prices of $0.14 and $0.18 per share. The fair value of the warrants of $689,934 was recorded as financing costs during the year ended September 30, 2018 and was based on a probability affected Black-Scholes Merton option pricing model with stock prices of $0.13 and $0.14, volatility of 124.60% and 124.73% and risk-free rates of 2.37% and 2.43%. In addition to the warrants, the Company offered certain loan holders, who were not officers or directors, to convert at a rate below the market price of the stock on the date of conversion. An aggregate of 218,452 additional common shares were issued to these loan holders with a value of $30,583 on the date of conversion. The Company recorded the amount as a financing cost during the year ended September 30, 2018. As of September 30, 2018, loans payable from officers and shareholders of $66,000 were outstanding.

Convertible Note Agreements

Convertible Note Agreements	12 Months Ended
	Sep. 30, 2018
Debt Disclosure [Abstract]
Convertible Note Agreements	NOTE 6 – CONVERTIBLE NOTE AGREEMENTS September 30, 2018 September 30, 2017 Convertible note payable (a) $ - $ 165,000 Convertible note payable (b) 165,000 - Convertible note payable (c) 110,000 - Debt discount – unamortized balance (72,078 ) (115,116 ) Convertible notes payable, net $ 202,922 $ 49,884 (a) In July 2017, the Company entered into a Convertible Note Payable Agreement with an individual under which the Company borrowed $165,000. Net proceeds received by the Company under the agreement were $150,000. In connection with the agreement, the Company issued the individual 165,000 restricted shares of its common stock with a fair value of $51,150 and warrants to purchase 330,000 shares of its common stock, which vested upon grant. The warrants expire five years from the date of grant and have an exercise price of $0.50 per share. The note payable accrues interest at eight percent per annum, is unsecured and is convertible at any time after the 90 th On the date of the agreement, the closing price of the common stock was $0.31 per share. As the conversion price embedded in the note agreement was below the trading price of the common stock on the date of issuance, a beneficial conversion feature (BCF) was recognized at the date of issuance. The Company recognized a debt discount at the date of issuance in the aggregate amount of $150,000 related to the relative fair value of the warrants and beneficial conversion features, which comprised $94,704 related to the intrinsic value of beneficial conversion features and $55,296 related to the relative fair value of the warrants. The aggregate fair value of the warrants of $87,582 was based on Black-Scholes Merton option pricing model with a stock price of $0.31, volatility of 139.98% and risk-free rate of 1.28%. The unamortized balance of the debt discount at September 30, 2017 was $115,116. The agreement also included a clause that allowed for the individual to receive additional shares if the price of the stock declined as of February 28, 2018 (the maturity date). The price of the stock on that date was $0.12 per share, causing the Company to issue the individual an additional 186,849 shares of its common stock. During the year ended September 30, 2018, the Company recorded a financing cost of $22,422 relating to the issuance of these shares. On March 5, 2018, the Company modified the conversion price on the note payable from $0.25 per share to $0.10 per share. On that date, the reduction in the conversion price allowed for the individual to convert an additional 990,000 shares with a fair value of $0.16 per share. The total amount of expense the Company recognized relating to the modification was $158,400. Also, on March 5, 2018, the Company modified the exercise price on the attached warrants from $0.50 per share to $0.20 per share. The total amount of the cost the Company recognized relating to the modification was $5,445. The maturity date of the note was also extended until April 30, 2018. During the year ended September 30, 2018, the individual converted $165,000 of the convertible note payable and $9,563 of accrued interest into 1,745,631 shares of the Company’s common stock. During the year ended September 30, 2018, the Company amortized the remaining $115,116 of debt discount, leaving no unamortized balance at September 30, 2018. (b) On March 5, 2018, the Company entered into another Convertible Note Payable Agreement with the same individual under which the Company borrowed an additional $165,000. Net proceeds received by the Company under the agreement after payment of a $15,000 fee to the lender was $150,000. In connection with the agreement, the Company issued the individual 300,000 restricted shares of its common stock with a fair value of $48,000 and warrants to purchase 660,000 shares of its common stock, which vested upon grant. The warrants expire five years from the date of grant and have an exercise price of $0.20 per share. The note payable accrues interest at eight percent per annum, is unsecured and is convertible at any time after the 90 th The Company calculated the related fair value of the warrants issued to the noteholder to be $55,032 using a Black Scholes Merton option pricing model and performing a relative value calculation. The Company then made a calculation to determine if a beneficial conversion feature (BCF) existed. The beneficial conversion was based upon the effective conversion price based on the proceeds received that were allocated to the convertible instrument. Based upon the Company’s calculation, it was determined that a beneficial conversion feature existed amounting to $94,968 and was recorded as a debt discount. As such the Company recognized a debt discount at the date of issuance in the aggregate amount of $165,000 relating to the $15,000 fees paid to the lender, the relative value of the warrants and the BCF. The note discount is being amortized over the term of the note and the unamortized portion is recognized as a reduction to the carrying amount of the Convertible note (a valuation debt discount). During the year ended September 30, 2018, the Company amortized $161,163 of debt discount, leaving an unamortized balance of $3,837 at September 30, 2018. The agreement also included a clause that allowed for the individual to receive additional shares if the price of the stock declined as of September 5, 2018. The price of the stock on that date was $0.13 per share, causing the Company to issue the individual an additional 60,902 shares of its common stock. The Company recorded a financing cost of $7,917 relating to the issuance of these shares. In addition, the Company recorded an additional finance cost of $48,000 related to the fair value of the 300,000 shares of common stock granted at the date issuance. (c) On July 11, 2018, the Company entered into another Convertible Note Payable Agreement with the same individual under which the Company borrowed an additional $110,000. Net proceeds received by the Company under the agreement after payment of a $10,000 fee to the lender was $100,000. In connection with the agreement, the Company issued the individual 200,000 restricted shares of its common stock with a fair value of $36,000 and warrants to purchase 440,000 shares of its common stock, which vested upon grant. The warrants expire five years from the date of grant and have an exercise price of $0.18 per share. The note payable accrues interest at eight percent per annum, is unsecured and is convertible at any time after the 90 th The Company calculated the related fair value of the warrants issued to the noteholder to be $66,440 using a Black Scholes Merton option pricing model and performing a relative value calculation. The Company then made a calculation to determine if a beneficial conversion feature (BCF) existed. The beneficial conversion was based upon the effective conversion price based on the proceeds received that were allocated to the convertible instrument. Based upon the Company’s calculation, it was determined that a beneficial conversion feature existed amounting to $33,560 and was recorded as a debt discount. As such the Company recognized a debt discount at the date of issuance in the aggregate amount of $110,000 relating to the $10,000 fees paid to the lender, the relative value of the warrants and the BCF. The note discount is being amortized over the term of the note and the unamortized portion is recognized as a reduction to the carrying amount of the Convertible note (a valuation debt discount). During the year ended September 30, 2018, the Company amortized $41,759 of debt discount, leaving an unamortized balance of $68,241 at September 30, 2018. In addition, the Company recorded an additional finance cost of $36,000 related to the fair value of the 200,000 shares of common stock granted at the date issuance.

Shareholders' Equity

Shareholders' Equity	12 Months Ended
	Sep. 30, 2018
Equity [Abstract]
Shareholders' Equity	NOTE 7 – SHAREHOLDERS’ EQUITY Authorized shares During the year ended September 30, 2016, the Company was authorized by its Articles of Incorporation to issue up to 75,000,000 shares of common stock, par value $0.001 per share. Holders of shares of common stock have full voting rights, one vote for each share held of record. Shareholders are entitled to receive dividends as may be declared by the Board out of funds legally available therefore and share pro rata in any distributions to shareholders upon liquidation. Shareholders have no conversion, pre-emptive or subscription rights. All outstanding shares of common stock are fully paid and non-assessable. During the year ended September 30, 2017, the Company amended its Articles of Incorporation to authorize it to issue up to 185,000,000 shares of common stock, par value $0.001 per share, through a filing of a Certificate of Amendment on January 12, 2017. As of September 30, 2018, and 2017 there were 100,952,569 and 90,284,916 shares of common stock issued and outstanding, respectively. Common shares issued for cash During the year ended September 30, 2017, the Company received $884,600 from the sale of 5,837,500 shares of its common stock. In connection with the sales, the Company issued warrants to the shareholders to purchase 13,715,000 shares of the Company’s common stock. The warrants expire five years from the date of grant and have exercise prices ranging from $0.12 per share to $0.40 per share. Certain of these shares induced a “Favored Nation Clause”, which required issuance of further shares in the event that future sales of common stock went below $0.25 per share. See “Common Shares Issued in Connection with the Settlement of an Equity Agreement” below. During the year ended September 30, 2018, the Company received $177,000 from the sale of 1,614,286 shares of its common stock. In connection with the sales, the Company issued warrants to the shareholders to purchase 3,228,572 shares of the Company’s common stock. The warrants expire five years from the date of grant and have exercise prices of $0.15 and $0.18 per share. Common shares issued for services During the year ended September 30, 2017, the Company issued 450,000 shares of its common stock for services valued at $138,500. The shares were valued at the trading price of the common stock at the date of issuance. During the year ended September 30, 2018, the Company issued 770,000 shares of its common stock valued at $111,300 for services provided by WCUI and PSI consultants. The shares were valued at the trading price of the common stock at the date of issuance. Retirement of common shares in legal settlement During the year ended September 30, 2017, the Company reached a settlement agreement with the former shareholders of PSI. Under the settlement agreement, 250,000 shares of the Company’s common stock owned by the former owners was retired. Along with the retirement of the shares, liabilities owed to the former owners totaling to $260,027 were forgiven and were recorded as a gain on extinguishment of debt on the consolidated statement of operations for the year ended September 30, 2017 (see Note 3). Common Shares Issued in Connection with the Settlement of an Equity Agreement During the year ended September 30, 2017, the Company completed a sale of common stock and warrants with a subscriber whereby the Company sold to the subscriber 1,600,000 shares of common stock and warrants to acquire 1,600,000 shares of common at a price of $0.40 per share, for total purchase consideration of $400,000 ($0.25 per unit). The subscription agreement also included a Favored Nation clause that in the event a subsequent private offering occurs at a price less than $.25 per share that was paid by the subscriber, then the subscriber’s stock unit price shall be proportionately adjusted to the identical ration of 40% discount of the market price in the date of the subscription agreement. Upon issuance of the instrument, no liability for the Favored Nation clause was considered necessary as it was determined that ASC 480-10 did not apply as it is a conditional obligation embedded in a share. During the year ended September 2018, the Company sold 333,333 shares of common stock at $0.15 per share and a warrant to acquire 666,667 shares of common stock at $0.18 per share to an investor that triggered the Favored Nation clause. To avoid the issuance of any future potential shares, the Company and the subscriber entered in an agreement on May 15, 2018, whereby the Company would issue an additional 1,066,667 shares common stock to the subscriber, cancel the previously issued 1,600,000 warrants, and issue a new warrant to acquire 5,334,334 shares of common stock at $.18 per share. To account for the issuance, the Company determined that other than par value, no other value would be ascribed to the additional 1,066,667 shares of common stock that were issued and due under the Favored Nations clause for the reasons detailed above. The Company also determined that it should record the incremental difference of $433,000 between the fair value of the canceled warrant of $185,000 and the fair value of new warrant of $618,000 at the date of the agreement. Given that no services were provided to the Company, the difference in fair value of the warrants before and after the modification was treated as a deemed dividend. Subsequent to the above issuance, the Company and the shareholder entered into a settlement agreement that will eliminate the Favored Nation clause. As such, in November 2018, the Company issued 296,534 shares and a warrant to acquire 770,987 shares of common stock at $0.18 per share. The fair value of the shares issued was $17,792 and the fair value of the warrants was $38,935. As these values were part of a settlement agreement, the total amount of $56,727 was recorded as a financing cost during the year ended September 30, 2018. Stock Options On December 22, 2010, effective retroactively as of June 30, 2010, the Company’s Board of Directors approved the adoption of the “2010 Non-Qualified Stock Option Plan” (“2010 Option Plan”) by unanimous consent. The 2010 Option Plan was initiated to encourage and enable officers, directors, consultants, advisors and key employees of the Company to acquire and retain a proprietary interest in the Company by ownership of its common stock. A total of 7,500,000 of the authorized shares of the Company’s common stock may be subject to, or issued pursuant to, the terms of the plan. Effective January 1, 2018, the Board of Directors approved to increase the number of authorized shares of the Company’s common stock that may be subject to, or issued pursuant to, the terms of the plan from 7,500,000 to 30,000,000. The Company’s policy is to recognize compensation cost for awards with only service conditions and a graded vesting schedule on a straight-line basis over the requisite service period for the entire award. Additionally, the Company’s policy is to issue new shares of common stock to satisfy stock option exercises. The Company applied fair value accounting for all share based payments awards. The fair value of each option granted is estimated on the date of grant using the Black-Scholes option-pricing model. Grants during Fiscal Year Ended September 30, 2017 During the year ended September 30, 2017, the Company issued options to purchase 1,150,000 shares of its common stock to an officer and consultants of the Company with exercise prices ranging from $0.12 to $0.40 per share. The options vested immediately and expire five years from the date of grant. During the year ended September 30, 2017, the Company valued the options using a Black-Scholes option pricing model and recorded $220,009 of stock compensation for the value of the options. During the year ended September 30, 2017, the Company issued options to purchase 500,000 shares of its common stock to a Director, Dr. Jay Joshi, relating to the sale of NPC Inc. shares (see Note 3). The options had an exercise price of $0.24 per share, vested immediately and expire five years from the date of grant. During the year ended September 30, 2017, the Company valued the options using a Black-Scholes option-pricing model and recorded $106,350 for the value of the options, which was recorded as a cost to the Company in computing the total gain on the transaction (see Note 3). The assumptions used for options granted during the year ended September 30, 2017 are as follows: Exercise price $ 0.12 - 0.40 Expected dividends - Expected volatility 138.2% - 152.3% Risk free interest rate 0.96% - 1.39% Expected life of options 2.5 Grants during Fiscal Year Ended September 30, 2018 Options Granted in Accordance with Employment Agreements During the year ended September 30, 2018, the Company entered into employment agreements with four employees of SCI. Under the agreements, the Company issued options to purchase a combined total of 2,800,000 shares of its common stock with a fair value of $396,308. The options are exercisable over a term of five years, with exercise prices ranging from $0.10 to $0.19. The Company valued the options using a Black-Scholes option pricing model. A combined total of 675,000 shares vested in equal amounts over a three-month period, starting on January 1, 2018, with the remainder vesting in equal amounts over the following one year and two months. Further, beginning on January 1, 2018, they will be granted additional stock options to purchase up to an aggregate total of 275,000 shares of the Company’s common stock each quarter. The options are exercisable over a five-year period, are issuable on the last day of each quarter ending and vest immediately on the date of grant. All options accelerate and become fully vested upon the sale or change of control of the Company. During the year ended September 30, 2018, the Company recorded $271,804 of stock compensation for the value of the options, and as of September 30, 2018, unvested compensation of $28,063 remained that will be amortized over the remaining vesting period. Other Grants During the year ended September 30, 2018, the Company granted options to purchase 8,517,500 shares of its common stock to its officers, directors and employees with a fair value of $1,004,450. The options have an exercise price of $0.14 per share and expire five years from the date of grant. The shares will vest in various periods. The Company valued the options using a Black-Scholes option pricing model. During the year ended September 30, 2018, the Company recorded $340,699 of stock compensation for the value of the options, and as of September 30, 2018, unvested compensation of $663,750 remained that will be amortized over the remaining vesting period. The assumptions used for options granted during the year ended September 30, 2018 are as follows: Exercise price $ 0.10 - 0.19 Expected dividends - Expected volatility 121.1% - 130.2% Risk free interest rate 2.01% - 2.85% Expected life of options 2.5 The table below summarizes the Company’s stock option activities for the years ended September 30, 2018 and 2017: Number of Option Shares Exercise Price Range Per Share Weighted Average Exercise Price Fair Value at Date of Grant Balance, September 30, 2016 5,227,500 $ 0.01 – 2.00 $ 0.60 $ 1,539,269 Granted 1,650,000 0.12 – 0.40 0.21 326,359 Cancelled (5,000 ) 0.09 0.09 - Exercised - - - - Expired (50,000 ) 1.00 1.00 - Balance, September 30, 2017 6,822,500 $ 0.10 - 2.00 $ 0.51 $ 1,865,628 Granted 11,317,500 0.10 - 0.19 0.14 1,379,127 Cancelled (183,333 ) 0.14 0.14 - Exercised - - - - Expired (10,000 ) 0.75 0.75 - Balance, September 30, 2018 17,946,667 $ 0.10 – 2.00 $ 0.28 $ 3,244,755 Vested and exercisable, September 30, 2018 11,693,095 $ 0.10 - 2.00 $ 0.36 $ 2,149,818 Unvested, September 30, 2018 6,253,572 $ 0.14 – 0.19 $ 0.15 $ 1,094,937 There was no aggregate intrinsic value for option shares outstanding at September 30, 2018. The following table summarizes information concerning outstanding and exercisable options as of September 30, 2018: Options Outstanding Options Exercisable Range of Exercise Prices Number Outstanding Average Remaining Contractual Life (in years) Weighted Average Exercise Price Number Exercisable Average Remaining Contractual Life (in years) Weighted Average Exercise Price $ 0.01 - 0.39 14,434,167 4.04 $ 0.15 8,180,595 3.71 $ 0.15 0.40 - 0.99 2,112,500 0.56 0.40 2,112,500 0.56 0.40 1.00 - 1.99 750,000 2.25 1.00 750,000 2.25 1.00 2.00 650,000 2.25 2.00 650,000 2.25 2.00 $ 0.01 - 2.00 17,946,667 3.41 $ 0.28 11,693,095 2.97 $ 0.36 As of September 30, 2018, there were 12,053,333 shares of stock options remaining available for issuance under the 2010 Plan. Stock Warrants During the year ended September 30, 2017: ● The Company issued warrants to purchase 13,715,000 shares with exercise prices of $0.12 and $0.40 per share as part of the sale of equity units. The warrants expire five years from the date of grant. ● The Company issued warrants to purchase 330,000 shares with an exercise price of $0.31 per share in connection with the issuance of a convertible note payable (see Note 6). The warrants expire five years from the date of grant. ● Warrants were exercised to purchase 4,065,414 shares of the Company’s common stock for $3,000. During the year ended September 30, 2018: ● The Company issued warrants to purchase 3,228,572 shares with exercise prices of $0.15 and $0.18 per share as part of the sale of equity units. The warrants expire five years from the date of grant. ● The Company issued warrants to purchase 1,100,000 shares with an exercise price of $0.20 per share in connection with the issuance of a convertible notes payable (see Note 6). The warrants expire five years from the date of grant. ● The Company issued warrants to purchase 6,038,336 shares with exercise prices of $0.14 and $0.18 per share in connection with the conversion of loans payable from officers and shareholders (see Note 5). ● The Company issued warrants to purchase 6,104,322 shares with an exercise price of $0.18 per share in connection with the initial equity agreement and the settlement of that equity agreement. Also, in connection with the agreement, a warrant to purchase 1,600,000 shares was also cancelled with an exercise price of $0.40 per share. ● Warrants were exercised to purchase 1,407,619 shares of the Company’s common stock for $170,914. The table below summarizes the Company’s warrants activities for the years ended September 30, 2018 and 2017: Number of Warrant Shares Exercise Price Range Per Share Weighted Average Exercise Price Fair Value at Date of Issuance Balance, September 30, 2016 54,938,158 $ 0.01 - 2.31 $ 0.25 $ 2,063,637 Granted 14,045,000 0.12 - 0.40 0.19 87,582 Canceled - - - - Exercised (4,065,414 ) 0.12 – 0.25 0.15 - Expired (756,440 ) 0.45 - 2.31 0.86 - Balance, September 30, 2017 64,161,304 $ 0.12 - 1.00 $ 0.24 $ 2,151,219 Granted 16,471,230 0.14 - 0.20 0.17 1,283,341 Cancelled (1,600,000 ) 0.40 0.40 - Exercised (1,407,619 ) 0.12 - 0.15 0.12 - Expired (9,717,187 ) 0.30 - 2.31 0.56 - Balance, September 30, 2018 67,907,728 $ 0.12 - 1.00 $ 0.17 $ 3,434,560 Vested and exercisable, September 30, 2018 67,907,728 $ 0.12 - 1.00 $ 0.17 $ 3,434,560 Unvested, September 30, 2018 - $ - $ - $ - There was no aggregate intrinsic value for warrant shares outstanding at September 30, 2018. The following table summarizes information concerning outstanding and exercisable warrants as of September 30, 2018: Warrants Outstanding Warrants Exercisable Range of Exercise Prices Number Outstanding Average Remaining Contractual Life (in years) Weighted Average Exercise Price Number Exercisable Average Remaining Contractual Life (in years) Weighted Average Exercise Price $ 0.12 – 0.20 58,994,670 3.04 $ 0.15 58,994,670 3.04 $ 0.15 0.21 – 0.49 8,574,570 1.78 0.28 8,574,570 1.78 0.28 0.50 – 1.00 338,488 0.78 0.68 338,488 0.78 0.68 $ 0.12 – 1.00 67,907,728 2.87 $ 0.17 67,907,728 2.87 $ 0.17

Settlement of Accrued Liabiliti

Settlement of Accrued Liabilities Acquired with PSI Acquisition	12 Months Ended
	Sep. 30, 2018
Business Combinations [Abstract]
Settlement of Accrued Liabilities Acquired with PSI Acquisition	NOTE 8 – SETTLEMENT OF ACCRUED LIABILITIES ACQUIRED WITH PSI ACQUISITION Edwin Longo was a principal in Psoria-Shield, Inc. (PSI), a company that was purchased by Wellness Center in 2012. Prior to the acquisition of PSI, Mr. Longo made advances of $224,444 to PSI that were outstanding at the time Wellness acquired that company. Mr. Longo had filed a claim against Wellness and PSI for payment of those advances. In February 2017, through the Circuit Court of the 13th Judicial Circuit in and for Hillsborough County, Florida, a Final Settlement Agreement (“Settlement Agreement”) was executed between the Company, Longo and certain other parties. The Settlement Agreement provided for, among other matters, the transfer of all right, title and interest of 250,000 common shares of Wellness held by certain parties to the Settlement Agreement back to Wellness, and the release of Wellness from any and all claims against the Company by Longo, including but not limited to the advances owed to him of $224,444. In accounting for the Settlement Agreement on the Company’s statement of operations for the year ended September 30, 2017, the balance of the amount owed to Longo of $224,444, plus another $64,333 of long outstanding or improperly recorded accounts payable, was canceled and accounted for as gain on settlement in an aggregate amount of $288,777.

Segment Reporting

Segment Reporting	12 Months Ended
	Sep. 30, 2018
Segment Reporting [Abstract]
Segment Reporting	NOTE 9 – SEGMENT REPORTING Reportable segments are components of an enterprise about which separate financial information is available and that is evaluated regularly by the chief operating decision maker in deciding how to allocate resources and in assessing performance. The Company’s reportable segments are based on products and services, geography, legal structure, management structure, or any other manner in which management disaggregates a company. During the year ended September 30, 2017, the Company discontinued operations of its NPC segment (see Note 3). The Company operates in the following business segments: (i) Medical Devices: (ii) Authentication and Encryption Products and Services: The detailed segment information of the Company is as follows: Wellness Center USA, Inc. Assets By Segments September 30, 2018 Corporate Medical Devices Authentication and Encryption Total ASSETS Current Assets Cash $ 331 $ 1,452 $ 2,427 $ 4,210 Prepaid expenses and other current assets - - 1,550 1,550 Total current assets 331 1,452 3,977 5,760 Property and equipment, net - - 2,619 2,619 Other assets 15,000 1,760 - 16,760 Total other assets 15,000 1,760 2,619 19,379 TOTAL ASSETS $ 15,331 $ 3,212 $ 6,596 $ 25,139 Wellness Center USA, Inc. Operations by Segments For the Year Ended September 30, 2018 Corporate Medical Devices Authentication and Encryption Total Sales: Trade $ - $ 45,000 $ 95,023 $ 140,023 Consulting services - - 73,700 73,700 Total Sales - 45,000 168,723 213,723 Cost of goods sold - - 79,960 79,960 Gross profit - 45,000 88,763 133,763 Operating expenses 1,179,937 224,196 822,229 2,226,362 Loss from operations $ (1,179,937 ) $ (179,196 ) $ (733,466 ) $ (2,092,599 ) Wellness Center USA, Inc. Operations by Segments For the Year Ended September 30, 2017 Corporate Medical Devices Authentication and Encryption Total Sales: Trade $ - $ 180,999 $ 28,600 $ 209,599 Consulting services - - 63,125 63,125 Total Sales - 180,999 91,725 272,724 Cost of goods sold - 71,827 75,117 146,944 Gross profit - 109,172 16,608 125,780 Operating expenses 1,066,227 436,557 626,400 2,129,184 Loss from operations $ (1,066,227 ) $ (327,385 ) $ (609,792 ) $ (2,003,404 )

Commitments

Commitments	12 Months Ended
	Sep. 30, 2018
Commitments and Contingencies Disclosure [Abstract]
Commitments	NOTE 10 – COMMITMENTS Operating Leases The Company leases its corporate office facilities under a non-cancellable lease agreement. The lease was initiated in July 2016 and expires February 28, 2024. The lease contains escalating rent payments and free rent periods. The Company accounts for the rent expense on a straight-line basis. At September 30, 2018 and 2017, the Company recorded a deferred rent obligation of $130,260 and $85,294, respectively, relating to the lease. Commencing on October 1, 2016, the Company’s wholly-owned subsidiary, StealthCo, entered into a non-cancellable lease agreement to lease its office facilities in Oak Ridge, Tennessee. The term of the lease is five years and expires September 30, 2021. Minimum annual rental commitments under non-cancelable leases at September 30, 2018 are as follows: Years ending September 30, Amount 2019 $ 145,812 2020 164,614 2021 184,583 2022 152,709 2023 158,527 Thereafter 67,871 TOTAL $ 874,116 Rent expense was $188,801 and $183,685 for the years ended September 30, 2018 and 2017, respectively. Legal Matters The Company is periodically engaged in legal proceedings arising from and relating to its business operations. We currently are not involved in any litigation that we believe could have a material adverse effect on our financial condition or results of operations. There is no action, suit, proceeding, inquiry or investigation before or by any court, public board, government agency, self-regulatory organization or body pending or, to the knowledge of the executive officers of our Company or any of our subsidiaries, threatened against or affecting our Company, our common stock, any of our subsidiaries or of our Company’s or our subsidiaries’ officers or directors in their capacities as such, in which an adverse decision could have a material adverse effect on our financial condition or results of operations. In June, 2015, the Company and its then CEO, Mr. Andrew Kandelapas, received a formal order of investigation from the Chicago Regional Staff of the SEC. The Company and its then CEO cooperated and delivered requested documents, testimony, and tolling agreements. In May, 2017, the Staff issued a Wells Notice stating its preliminary determination to recommend an enforcement action against the Company and its then CEO based on possible violations of Section 17(a) of the Securities Act, Sections 15 (a) and 10(b) of the Exchange Act, and Rule 10b-5 thereunder. The Staff would allege, among other things, that periodic reports issued during 2013 and 2014 were misleading because they failed to disclose or mischaracterized as “salary”, “prepayments” or “loans,” several payments totaling $450,000 made to said CEO during those years without prior Board approval; that two press releases issued in 2015 touted shipments of several Psoria-Light devices that were not closed sales; and that we used an unregistered broker-dealer to identify and solicit potential investors during 2013, 2015 and 2017. In periodic reports on Forms 10-K and 10-Q for the periods ending September 30, 2017 and December 31, 2017, respectively, the Company disclosed that on May 25, 2017, the SEC’s Chicago Regional Office informed it that it had made a preliminary determination to recommend filing of an enforcement action against the Company and its CEO based on possible violations of Section 10(b) of the Exchange Act and Rule 10b-5 thereunder, and Section 17(a) of the Securities Act, and Section 15(a) of the Exchange Act. Subsequent discussions resulted in the submission of an Offer of Settlement (“Settlement”) through an administrative cease and desist action on November 17, 2017, which was accepted by the SEC on April 12, 2018, as disclosed on Form 8-K filed April 18, 2018. Pursuant to the Settlement, the Company neither admitted nor denied any of the allegations, but was enjoined from violating the above-referenced Sections and Rule. The Settlement imposed no financial penalties or sanctions against the Company. The Form 8-K also disclosed that on April 13, 2018, the SEC filed a separate complaint against the CEO in the U.S. District Court for the Northern District of Illinois, asserting the allegations noted above, as well as allegations that he manipulated the price of company shares through undisclosed trading, realizing more than $130,000 from such trading. On the date of filing, the CEO voluntarily resigned as an officer and director of the Company. Without admitting or denying the allegations, the CEO consented to the entry of the judgment, which was entered on September 26, 2018 by the U.S. District Court for the Northern District of Illinois. The judgment permanently enjoined him from violating the anti-fraud provisions of Section 17(a) of the Securities Act of 1933, Section 10(b) of the Securities Exchange Act of 1934 and Rule 10b-5 thereunder, and the broker registration provisions of Section 15(a) of the Exchange Act. It also bars him from serving as an officer or director of a public company and from participating in penny stock offerings, and ordered disgorgement and interest and penalties to be determined by the court. Employment Contracts During the year ended September 30, 2018, the Company entered into employment agreements with four employees of StealthCo (including Ricky Howard), under which their employment shall continue in effect for a period of three years. Each agreement allows for a base salary with an accumulated amount of $350,000 that can increase each year based on certain profitability goals of SCI or SCI products. Under the agreements, the Company will issue options to purchase shares of its common stock as discussed in Note 7. Subsequent to September 30, 2018, three of the four employees were no longer employed by the Company.

Income Taxes

Income Taxes	12 Months Ended
	Sep. 30, 2018
Income Tax Disclosure [Abstract]
Income Taxes	NOTE 11 – INCOME TAXES At September 30, 2018, the Company had net operating loss (“NOL”) carryforwards for federal income tax purposes of approximately $16 million that may be offset against future taxable income through 2038. No tax benefit has been reported with respect to these net operating loss carryforwards because the Company believes that the realization of the Company’s net deferred tax assets of approximately $6,000,000 was not considered more likely than not and accordingly, the potential tax benefits of the net loss carryforwards are offset by a full valuation allowance. Deferred tax assets consist primarily of the tax effect of NOL carryforwards. The Company has provided a full valuation allowance on the deferred tax assets because of the uncertainty regarding the probability of its realization. The Company’s effective income tax rate differs from the amount computed by applying the federal statutory income tax rate to loss before income taxes as follows: September 30, September 30, Income tax benefit at federal statutory rate (21.0 )% (34.0 )% State income tax benefit, net of federal benefit (4.0 )% (6.0 )% Change in valuation allowance 25.0 % 40.0 % Income taxes at effective income tax rate - % - % The components of deferred taxes consist of the following at September 30, 2018 and 2017: September 30, 2018 September 30, 2017 Net operating loss carryforwards $ 5,884,083 $ 5,535,673 Less: Valuation allowance (5,884,083 ) (5,535,673 ) Net deferred tax assets $ - $ -

Related Party Transactions

Related Party Transactions	12 Months Ended
	Sep. 30, 2018
Related Party Transactions [Abstract]
Related Party Transactions	NOTE 12 – RELATED PARTY TRANSACTIONS Compensation of Former Chairman and Chief Executive Officer During the years ended September 30, 2018 and 2017, the Company's former Chairman and Chief Executive Officer, Andrew J. Kandalepas, was paid compensation of $182,375 and $250,000, respectively. During the year ended September 30, 2018, he was also granted stock options to purchase 1,300,000 shares of the Company's common stock at an exercise price of $0.14 per share. The options expire five years from the date of grant and the shares will vest in various periods. Mr. Kandalepas resigned as an officer and director in April 2018. As of September 30, 2018 and 2017, $81,965 and $13,440 of accrued compensation was owed to Mr. Kandalepas.

Subsequent Events

Subsequent Events	12 Months Ended
	Sep. 30, 2018
Subsequent Events [Abstract]
Subsequent Events	NOTE 13 – SUBSEQUENT EVENTS On November 15, 2018, Wellness Center USA, Inc. (“WCUI”) and its wholly-owned subsidiary, Psoria-Shield, Inc. (“PSI”), entered into a Joint Venture Agreement with PSI Gen 2 Funding, Inc. (“GEN2”), an Illinois corporation, to further development, marketing, licensing and/or sale of PSI technology and products. The Joint Venture will be conducted through NEO PHOTOTHERAPY, LLC, a recently formed Illinois limited liability company (“NEO”), with principal offices and records to be maintained at WCUI’s offices. PSI and GEN2 will be the members of NEO, owning 58.5% and 28.0%, respectively, of the limited liability interests (“Units”) issued in connection with the organization of NEO. An additional 13.5% of such Units will be reserved for issuance as incentives for key employees and consultants retained from time to time by NEO in connection with the Venture. PSI and GEN2 will manage NEO’s day-to-day operations. PSI will contribute PSI Technology to NEO and GEN2 will contribute $700,000, through the period ending January 31, 2019. Repayment of the $700,000 investment by GEN2 will begin through and upon the date which NEO has realized and retained cumulative Net Income/Distributable Cash in the amount of $300,000. Distributions thereafter will be made to PSI, GEN2 and other members in proportion to their respective Unit ownership, at the times and in the manner determined from time to time by the managers, in their sole discretion. GEN2 consists of accredited investors, and investment participation from several WCUI officers and directors, including Calvin R. O’Harrow and Roy M. Harsch. Through November 2018, PSI was operated by Psoria Development Company LLC, an Illinois limited liability company (“PDC”), a joint venture between WCUI/PSI and The Medical Alliance, Inc., a Florida corporation (“TMA”). In December 2018, the PDC Joint Venture Agreement was terminated. Further development, marketing, licensing and/or sales of PSI Technology and products is expected to be conducted through NEO.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Sep. 30, 2018
Accounting Policies [Abstract]
Basis of Consolidation	Basis of Consolidation The Company’s consolidated subsidiaries and/or entities are as follows: Name of consolidated subsidiary or entity State or other jurisdiction of incorporation or organization Date of incorporation or formation (date of acquisition/disposition, if applicable) Attributable interest Psoria-Shield Inc. (“PSI”) The State of Florida June 17, 2009 (August 24, 2012) 100% StealthCo, Inc. (“StealthCo”) The State of Illinois March 18, 2014 100% Psoria Development Company LLC. (“PDC”) The State of Illinois January 15, 2015 50%
Use of Estimates	Use of Estimates The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the U.S requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the financial statement date, and reported amounts of revenue and expenses during the reporting period. Significant estimates are used in the valuation of accounts receivable and allowance for uncollectible amounts, inventory and obsolescence reserves, accruals for potential liabilities, valuations of stock-based compensation, realization of deferred tax assets, among others. Actual results could differ from these estimates.
Income (Loss) Per Share	Income (Loss) Per Share Basic loss per share is computed by dividing net loss applicable to common shareholders by the weighted average number of outstanding common shares during the period. Diluted loss per share is computed by dividing the net loss applicable to common shareholders by the weighted average number of common shares outstanding plus the number of additional common shares that would have been outstanding if all dilutive potential common shares had been issued. For the years ended September 30, 2018 and 2017, the basic and diluted shares outstanding were the same, as potentially dilutive shares were considered anti-dilutive. At September 30, 2018 and 2017, the dilutive impact of outstanding stock options for 17,946,667 and 6,822,500 shares, respectively, and outstanding warrants for 67,907,728 and 64,161,304 shares, respectively, have been excluded because their impact on the loss per share is anti-dilutive.
Revenue Recognition	Revenue Recognition The Company recognizes revenue when it is realized or realizable and earned. The Company considers revenue realized or realizable and earned when all of the following criteria are met: (i) persuasive evidence of an arrangement exists, (ii) the product has been shipped or the services have been rendered to the customer, (iii) the sales price is fixed or determinable, and (iv) collectability is reasonably assured. In addition to the aforementioned general policy, the following are the specific revenue recognition policies for each major category of revenue: (i) Sale of products : (ii) Consulting services: Payments received before the relevant criteria for revenue recognition are satisfied are recorded as deferred revenue. Deferred revenue at September 30, 2018 and 2017 was $8,624 and $55,098, respectively.
Accounts Receivable	Accounts Receivable The Company evaluates the collectability of its trade accounts receivable based on a number of factors. In circumstances where the Company becomes aware of a specific customer’s inability to meet its financial obligations to the Company, a specific reserve for bad debts is estimated and recorded, which reduces the recognized receivable to the estimated amount the Company believes will ultimately be collected. In addition to specific customer identification of potential bad debts, bad debt charges are recorded based on the Company’s historical losses and an overall assessment of past due trade accounts receivable outstanding. The allowance for doubtful accounts and returns is established through a provision reducing the carrying value of receivables. At September 30, 2018 and 2017, no allowance for doubtful accounts and returns was considered necessary.
Inventories	Inventories Inventories are stated at the lower of cost or market. Cost is computed on a first-in, first-out basis. At September 30, 2017, primarily all of the inventories totaling to $12,335 consisted of finished goods. At September 30, 2018, the Company’s net inventories had no value. The Company provides inventory reserves based on excess and obsolete inventories determined primarily by future demand forecasts. The write down amount is measured as the difference between the cost of the inventory and market based upon assumptions about future demand and charged to the provision for inventory, which is a component of cost of sales. At the point of the loss recognition, a new, lower cost basis for that inventory is established, and subsequent changes in facts and circumstances do not result in the restoration or increase in that newly established cost basis. During the year ended September 30, 2018, the Company provided a reserve of $12,335 that is included in cost of goods sold to account for its estimate of slow moving and obsolete inventory.
Property and Equipment	Property and Equipment Property and equipment are carried at cost less accumulated depreciation and amortization. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets. The Company has determined the estimated useful lives of its property and equipment, as follows: Computer equipment 5 years Medical equipment 5 years Furniture and fixtures 7 years Vehicles 3 years Software 3 years Maintenance and repairs are charged to expense as incurred. The cost and accumulated depreciation of assets sold or otherwise disposed of are removed from the related accounts and the resulting gain or loss is reflected in the statements of operations. Management assesses the carrying value of property and equipment whenever events or changes in circumstances indicate that the carrying value may not be recoverable. If there is indication of impairment, management prepares an estimate of future cash flows expected to result from the use of the asset and its eventual disposition. If these cash flows are less than the carrying amount of the asset, an impairment loss is recognized to write down the asset to its estimated fair value.
Income Taxes	Income Taxes Income tax expense is based on pretax financial accounting income. Deferred tax assets and liabilities are recognized for the expected tax consequences of temporary differences between the tax bases of assets and liabilities and their reported amounts. Valuation allowances are recorded to reduce deferred tax assets to the amount that will more likely than not be realized. The Company recorded a valuation allowance against its deferred tax assets as of September 30, 2018 and 2017. The Company accounts for uncertainty in income taxes using a two-step approach to recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount that is more than 50 percent likely of being realized upon settlement. The Company classifies the liability for unrecognized tax benefits as current to the extent that the Company anticipates payment (or receipt) of cash within one year. Interest and penalties related to uncertain tax positions are recognized in the provision for income taxes.
Fair Value Measurements	Fair Value measurements The Company determines the fair value of its assets and liabilities based on the exchange price in U.S. dollars that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value maximize the use of observable inputs and minimize the use of unobservable inputs. The Company uses a fair value hierarchy with three levels of inputs, of which the first two are considered observable and the last unobservable, to measure fair value: ● Level 1 — ● Level 2 — ● Level 3 — The carrying amounts of financial instruments such as cash, accounts receivable, inventories, and accounts payable and accrued liabilities, approximate the related fair values due to the short-term maturities of these instruments.
Non-Controlling Interest	Non-controlling Interest Non-controlling interest represents the non-controlling interest holder’s proportionate share of the equity of the Company’s majority-owned subsidiary, PDC. Non-controlling interest is adjusted for the non-controlling interest holder’s proportionate share of the earnings or losses and other comprehensive income (loss), if any, and the non-controlling interest continues to be attributed its share of losses even if that attribution results in a deficit non-controlling interest balance.
Stock-Based Compensation	Stock-Based Compensation The Company periodically grants stock options and warrants to employees and non-employees in non-capital raising transactions as compensation for services rendered. The Company accounts for stock option and stock warrant grants to employees based on the authoritative guidance provided by the Financial Accounting Standards Board where the value of the award is measured on the date of grant and recognized over the vesting period. The Company accounts for stock option and stock warrant grants to non-employees in accordance with the authoritative guidance of the Financial Accounting Standards Board where the value of the stock compensation is determined based upon the measurement date at either a) the date at which a performance commitment is reached, or b) at the date at which the necessary performance to earn the equity instruments is complete. Non-employee stock-based compensation charges generally are amortized over the vesting period on a straight-line basis. In certain circumstances where there are no future performance requirements by the non-employee, option or warrant grants are immediately vested and the total stock-based compensation charge is recorded in the period of the measurement date. The fair value of the Company’s common stock option and warrant grants are estimated using a Black-Scholes Merton option pricing model, which uses certain assumptions related to risk-free interest rates, expected volatility, expected life of the common stock options, estimated forfeitures and future dividends. Compensation expense is recorded based upon the value derived from the Black-Scholes option pricing model, and based on actual experience. The assumptions used in the Black-Scholes Merton option pricing model could materially affect compensation expense recorded in future periods.
Recently Issued Accounting Pronouncements	Recently Issued Accounting Pronouncements In May 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2014-09, Revenue from Contracts with Customers. ASU 2014-09 is a comprehensive revenue recognition standard that will supersede nearly all existing revenue recognition guidance under current U.S. GAAP and replace it with a principle-based approach for determining revenue recognition. ASU 2014-09 will require that companies recognize revenue based on the value of transferred goods or services as they occur in the contract. The ASU also will require additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to obtain or fulfill a contract. ASU 2014-09 is effective for interim and annual periods beginning after December 15, 2017. Early adoption is permitted only in annual reporting periods beginning after December 15, 2016, including interim periods therein. Entities will be able to transition to the standard either retrospectively or as a cumulative-effect adjustment as of the date of adoption. The Company is in the process of evaluating the impact of ASU 2014-09 on the Company’s financial statements and disclosures but does not believe the adoption of this standard will have a material effect on the Company, if any. In February 2016, the FASB issued Accounting Standards Update (ASU) No. 2016-02, Leases. ASU 2016-02 requires a lessee to record a right of use asset and a corresponding lease liability on the balance sheet for all leases with terms longer than 12 months. ASU 2016-02 is effective for all interim and annual reporting periods beginning after December 15, 2018. Early adoption is permitted. A modified retrospective transition approach is required for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. The Company is in the process of evaluating the impact of ASU 2016-02 on the Company’s financial statements and disclosures. Other recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the Securities and Exchange Commission did not or are not believed by management to have a material impact on the Company’s present or future consolidated financial statements.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Sep. 30, 2018
Accounting Policies [Abstract]
Schedule of Company's Consolidated Subsidiaries	The Company’s consolidated subsidiaries and/or entities are as follows: Name of consolidated subsidiary or entity State or other jurisdiction of incorporation or organization Date of incorporation or formation (date of acquisition/disposition, if applicable) Attributable interest Psoria-Shield Inc. (“PSI”) The State of Florida June 17, 2009 (August 24, 2012) 100% StealthCo, Inc. (“StealthCo”) The State of Illinois March 18, 2014 100% Psoria Development Company LLC. (“PDC”) The State of Illinois January 15, 2015 50%
Schedule of Estimated Useful Lives of Property and Equipment	The Company has determined the estimated useful lives of its property and equipment, as follows: Computer equipment 5 years Medical equipment 5 years Furniture and fixtures 7 years Vehicles 3 years Software 3 years

Discontinued Operations (Tables

Discontinued Operations (Tables)	12 Months Ended
	Sep. 30, 2018
Discontinued Operations and Disposal Groups [Abstract]
Statement of Operations of Discontinued Operations	Year Ended September 30, 2017 Total Sales $ 83,826 Operating expenses 231,302 Loss from discontinued operations $ (147,476 ) Other income Gain from sale of discontinued operations $ 252,508

Property and Equipment (Tables)

Property and Equipment (Tables)	12 Months Ended
	Sep. 30, 2018
Property, Plant and Equipment [Abstract]
Schedule of Property and Equipment	Property and equipment consisted of the following at September 30, 2018 and 2017: September 30, 2018 September 30, 2017 Vehicles $ 15,000 $ 15,000 Computer equipment 10,456 10,456 Furniture and fixtures 23,998 23,998 Medical equipment 18,889 18,889 Software 23,207 23,207 Leasehold improvements 15,170 15,170 106,720 106,720 Less: accumulated depreciation and amortization (104,101 ) (101,594 ) Property and equipment, net $ 2,619 $ 5,126

Convertible Note Agreements (Ta

Convertible Note Agreements (Tables)	12 Months Ended
	Sep. 30, 2018
Debt Disclosure [Abstract]
Schedule of Convertible Notes Payable	September 30, 2018 September 30, 2017 Convertible note payable (a) $ - $ 165,000 Convertible note payable (b) 165,000 - Convertible note payable (c) 110,000 - Debt discount – unamortized balance (72,078 ) (115,116 ) Convertible notes payable, net $ 202,922 $ 49,884 (a) In July 2017, the Company entered into a Convertible Note Payable Agreement with an individual under which the Company borrowed $165,000. Net proceeds received by the Company under the agreement were $150,000. In connection with the agreement, the Company issued the individual 165,000 restricted shares of its common stock with a fair value of $51,150 and warrants to purchase 330,000 shares of its common stock, which vested upon grant. The warrants expire five years from the date of grant and have an exercise price of $0.50 per share. The note payable accrues interest at eight percent per annum, is unsecured and is convertible at any time after the 90 th On the date of the agreement, the closing price of the common stock was $0.31 per share. As the conversion price embedded in the note agreement was below the trading price of the common stock on the date of issuance, a beneficial conversion feature (BCF) was recognized at the date of issuance. The Company recognized a debt discount at the date of issuance in the aggregate amount of $150,000 related to the relative fair value of the warrants and beneficial conversion features, which comprised $94,704 related to the intrinsic value of beneficial conversion features and $55,296 related to the relative fair value of the warrants. The aggregate fair value of the warrants of $87,582 was based on Black-Scholes Merton option pricing model with a stock price of $0.31, volatility of 139.98% and risk-free rate of 1.28%. The unamortized balance of the debt discount at September 30, 2017 was $115,116. The agreement also included a clause that allowed for the individual to receive additional shares if the price of the stock declined as of February 28, 2018 (the maturity date). The price of the stock on that date was $0.12 per share, causing the Company to issue the individual an additional 186,849 shares of its common stock. During the year ended September 30, 2018, the Company recorded a financing cost of $22,422 relating to the issuance of these shares. On March 5, 2018, the Company modified the conversion price on the note payable from $0.25 per share to $0.10 per share. On that date, the reduction in the conversion price allowed for the individual to convert an additional 990,000 shares with a fair value of $0.16 per share. The total amount of expense the Company recognized relating to the modification was $158,400. Also, on March 5, 2018, the Company modified the exercise price on the attached warrants from $0.50 per share to $0.20 per share. The total amount of the cost the Company recognized relating to the modification was $5,445. The maturity date of the note was also extended until April 30, 2018. During the year ended September 30, 2018, the individual converted $165,000 of the convertible note payable and $9,563 of accrued interest into 1,745,631 shares of the Company’s common stock. During the year ended September 30, 2018, the Company amortized the remaining $115,116 of debt discount, leaving no unamortized balance at September 30, 2018. (b) On March 5, 2018, the Company entered into another Convertible Note Payable Agreement with the same individual under which the Company borrowed an additional $165,000. Net proceeds received by the Company under the agreement after payment of a $15,000 fee to the lender was $150,000. In connection with the agreement, the Company issued the individual 300,000 restricted shares of its common stock with a fair value of $48,000 and warrants to purchase 660,000 shares of its common stock, which vested upon grant. The warrants expire five years from the date of grant and have an exercise price of $0.20 per share. The note payable accrues interest at eight percent per annum, is unsecured and is convertible at any time after the 90 th The Company calculated the related fair value of the warrants issued to the noteholder to be $55,032 using a Black Scholes Merton option pricing model and performing a relative value calculation. The Company then made a calculation to determine if a beneficial conversion feature (BCF) existed. The beneficial conversion was based upon the effective conversion price based on the proceeds received that were allocated to the convertible instrument. Based upon the Company’s calculation, it was determined that a beneficial conversion feature existed amounting to $94,968 and was recorded as a debt discount. As such the Company recognized a debt discount at the date of issuance in the aggregate amount of $165,000 relating to the $15,000 fees paid to the lender, the relative value of the warrants and the BCF. The note discount is being amortized over the term of the note and the unamortized portion is recognized as a reduction to the carrying amount of the Convertible note (a valuation debt discount). During the year ended September 30, 2018, the Company amortized $161,163 of debt discount, leaving an unamortized balance of $3,837 at September 30, 2018. The agreement also included a clause that allowed for the individual to receive additional shares if the price of the stock declined as of September 5, 2018. The price of the stock on that date was $0.13 per share, causing the Company to issue the individual an additional 60,902 shares of its common stock. The Company recorded a financing cost of $7,917 relating to the issuance of these shares. In addition, the Company recorded an additional finance cost of $48,000 related to the fair value of the 300,000 shares of common stock granted at the date issuance. (c) On July 11, 2018, the Company entered into another Convertible Note Payable Agreement with the same individual under which the Company borrowed an additional $110,000. Net proceeds received by the Company under the agreement after payment of a $10,000 fee to the lender was $100,000. In connection with the agreement, the Company issued the individual 200,000 restricted shares of its common stock with a fair value of $36,000 and warrants to purchase 440,000 shares of its common stock, which vested upon grant. The warrants expire five years from the date of grant and have an exercise price of $0.18 per share. The note payable accrues interest at eight percent per annum, is unsecured and is convertible at any time after the 90 th The Company calculated the related fair value of the warrants issued to the noteholder to be $66,440 using a Black Scholes Merton option pricing model and performing a relative value calculation. The Company then made a calculation to determine if a beneficial conversion feature (BCF) existed. The beneficial conversion was based upon the effective conversion price based on the proceeds received that were allocated to the convertible instrument. Based upon the Company’s calculation, it was determined that a beneficial conversion feature existed amounting to $33,560 and was recorded as a debt discount. As such the Company recognized a debt discount at the date of issuance in the aggregate amount of $110,000 relating to the $10,000 fees paid to the lender, the relative value of the warrants and the BCF. The note discount is being amortized over the term of the note and the unamortized portion is recognized as a reduction to the carrying amount of the Convertible note (a valuation debt discount). During the year ended September 30, 2018, the Company amortized $41,759 of debt discount, leaving an unamortized balance of $68,241 at September 30, 2018. In addition, the Company recorded an additional finance cost of $36,000 related to the fair value of the 200,000 shares of common stock granted at the date issuance.

Shareholders' Equity (Tables)

Shareholders' Equity (Tables)	12 Months Ended
	Sep. 30, 2018
Equity [Abstract]
Schedule of Assumptions Used for Options Granted	The assumptions used for options granted during the year ended September 30, 2017 are as follows: Exercise price $ 0.12 - 0.40 Expected dividends - Expected volatility 138.2% - 152.3% Risk free interest rate 0.96% - 1.39% Expected life of options 2.5 The assumptions used for options granted during the year ended September 30, 2018 are as follows: Exercise price $ 0.10 - 0.19 Expected dividends - Expected volatility 121.1% - 130.2% Risk free interest rate 2.01% - 2.85% Expected life of options 2.5
Schedule of Stock Option Activity	The table below summarizes the Company’s stock option activities for the years ended September 30, 2018 and 2017: Number of Option Shares Exercise Price Range Per Share Weighted Average Exercise Price Fair Value at Date of Grant Balance, September 30, 2016 5,227,500 $ 0.01 – 2.00 $ 0.60 $ 1,539,269 Granted 1,650,000 0.12 – 0.40 0.21 326,359 Cancelled (5,000 ) 0.09 0.09 - Exercised - - - - Expired (50,000 ) 1.00 1.00 - Balance, September 30, 2017 6,822,500 $ 0.10 - 2.00 $ 0.51 $ 1,865,628 Granted 11,317,500 0.10 - 0.19 0.14 1,379,127 Cancelled (183,333 ) 0.14 0.14 - Exercised - - - - Expired (10,000 ) 0.75 0.75 - Balance, September 30, 2018 17,946,667 $ 0.10 – 2.00 $ 0.28 $ 3,244,755 Vested and exercisable, September 30, 2018 11,693,095 $ 0.10 - 2.00 $ 0.36 $ 2,149,818 Unvested, September 30, 2018 6,253,572 $ 0.14 – 0.19 $ 0.15 $ 1,094,937
Schedule of Outstanding and Exercisable Options by Exercise Price Range	The following table summarizes information concerning outstanding and exercisable options as of September 30, 2018: Options Outstanding Options Exercisable Range of Exercise Prices Number Outstanding Average Remaining Contractual Life (in years) Weighted Average Exercise Price Number Exercisable Average Remaining Contractual Life (in years) Weighted Average Exercise Price $ 0.01 - 0.39 14,434,167 4.04 $ 0.15 8,180,595 3.71 $ 0.15 0.40 - 0.99 2,112,500 0.56 0.40 2,112,500 0.56 0.40 1.00 - 1.99 750,000 2.25 1.00 750,000 2.25 1.00 2.00 650,000 2.25 2.00 650,000 2.25 2.00 $ 0.01 - 2.00 17,946,667 3.41 $ 0.28 11,693,095 2.97 $ 0.36
Schedule of Warrant Activity	The table below summarizes the Company’s warrants activities for the years ended September 30, 2018 and 2017: Number of Warrant Shares Exercise Price Range Per Share Weighted Average Exercise Price Fair Value at Date of Issuance Balance, September 30, 2016 54,938,158 $ 0.01 - 2.31 $ 0.25 $ 2,063,637 Granted 14,045,000 0.12 - 0.40 0.19 87,582 Canceled - - - - Exercised (4,065,414 ) 0.12 – 0.25 0.15 - Expired (756,440 ) 0.45 - 2.31 0.86 - Balance, September 30, 2017 64,161,304 $ 0.12 - 1.00 $ 0.24 $ 2,151,219 Granted 16,471,230 0.14 - 0.20 0.17 1,283,341 Cancelled (1,600,000 ) 0.40 0.40 - Exercised (1,407,619 ) 0.12 - 0.15 0.12 - Expired (9,717,187 ) 0.30 - 2.31 0.56 - Balance, September 30, 2018 67,907,728 $ 0.12 - 1.00 $ 0.17 $ 3,434,560 Vested and exercisable, September 30, 2018 67,907,728 $ 0.12 - 1.00 $ 0.17 $ 3,434,560 Unvested, September 30, 2018 - $ - $ - $ -
Schedule of Outstanding and Exercisable Warrants by Exercise Price Range	The following table summarizes information concerning outstanding and exercisable warrants as of September 30, 2018: Warrants Outstanding Warrants Exercisable Range of Exercise Prices Number Outstanding Average Remaining Contractual Life (in years) Weighted Average Exercise Price Number Exercisable Average Remaining Contractual Life (in years) Weighted Average Exercise Price $ 0.12 – 0.20 58,994,670 3.04 $ 0.15 58,994,670 3.04 $ 0.15 0.21 – 0.49 8,574,570 1.78 0.28 8,574,570 1.78 0.28 0.50 – 1.00 338,488 0.78 0.68 338,488 0.78 0.68 $ 0.12 – 1.00 67,907,728 2.87 $ 0.17 67,907,728 2.87 $ 0.17

Segment Reporting (Tables)

Segment Reporting (Tables)	12 Months Ended
	Sep. 30, 2018
Segment Reporting [Abstract]
Schedule of Assets of Reportable Segments	The detailed segment information of the Company is as follows: Wellness Center USA, Inc. Assets By Segments September 30, 2018 Corporate Medical Devices Authentication and Encryption Total ASSETS Current Assets Cash $ 331 $ 1,452 $ 2,427 $ 4,210 Prepaid expenses and other current assets - - 1,550 1,550 Total current assets 331 1,452 3,977 5,760 Property and equipment, net - - 2,619 2,619 Other assets 15,000 1,760 - 16,760 Total other assets 15,000 1,760 2,619 19,379 TOTAL ASSETS $ 15,331 $ 3,212 $ 6,596 $ 25,139
Schedule of Operations of Reportable Segments	Wellness Center USA, Inc. Operations by Segments For the Year Ended September 30, 2018 Corporate Medical Devices Authentication and Encryption Total Sales: Trade $ - $ 45,000 $ 95,023 $ 140,023 Consulting services - - 73,700 73,700 Total Sales - 45,000 168,723 213,723 Cost of goods sold - - 79,960 79,960 Gross profit - 45,000 88,763 133,763 Operating expenses 1,179,937 224,196 822,229 2,226,362 Loss from operations $ (1,179,937 ) $ (179,196 ) $ (733,466 ) $ (2,092,599 ) Wellness Center USA, Inc. Operations by Segments For the Year Ended September 30, 2017 Corporate Medical Devices Authentication and Encryption Total Sales: Trade $ - $ 180,999 $ 28,600 $ 209,599 Consulting services - - 63,125 63,125 Total Sales - 180,999 91,725 272,724 Cost of goods sold - 71,827 75,117 146,944 Gross profit - 109,172 16,608 125,780 Operating expenses 1,066,227 436,557 626,400 2,129,184 Loss from operations $ (1,066,227 ) $ (327,385 ) $ (609,792 ) $ (2,003,404 )

Commitments (Tables)

Commitments (Tables)	12 Months Ended
	Sep. 30, 2018
Commitments and Contingencies Disclosure [Abstract]
Summary of Minimum Annual Rental Commitments Under Non-cancelable Leases	Minimum annual rental commitments under non-cancelable leases at September 30, 2018 are as follows: Years ending September 30, Amount 2019 $ 145,812 2020 164,614 2021 184,583 2022 152,709 2023 158,527 Thereafter 67,871 TOTAL $ 874,116

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Sep. 30, 2018
Income Tax Disclosure [Abstract]
Schedule of Effective Income Tax Rate Reconciliation	The Company’s effective income tax rate differs from the amount computed by applying the federal statutory income tax rate to loss before income taxes as follows: September 30, 2018 September 30, 2017 Income tax benefit at federal statutory rate (21.0 )% (34.0 )% State income tax benefit, net of federal benefit (4.0 )% (6.0 )% Change in valuation allowance 25.0 % 40.0 % Income taxes at effective income tax rate - % - %
Schedule of Deferred Tax Assets and Liabilities	The components of deferred taxes consist of the following at September 30, 2018 and 2017: September 30, 2018 September 30, 2017 Net operating loss carryforwards $ 5,884,083 $ 5,535,673 Less: Valuation allowance (5,884,083 ) (5,535,673 ) Net deferred tax assets $ - $ -

Basis of Presentation (Details

Basis of Presentation (Details Narrative) - USD ($)	12 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Aug. 11, 2017	Sep. 30, 2016
Entity incorporation, state country name	Nevada
Net loss from continuing operations	$ (3,493,419)	$ (1,712,980)
Net cash used in operating activities from continuing operations	(1,037,073)	(1,634,176)
Shareholders' deficit	(825,160)	(290,449)		$ (754,700)
Cash on hand	4,210	$ 29,369		$ 81,749
Proceeds from sale of common stock, exercise of stock warrant and debt offering	$ 1,032,414
NPC Inc. [Member]
Ownership interest, percentage			100.00%

Summary of Significant Accoun_4

Summary of Significant Accounting Policies (Details Narrative) - USD ($)	12 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
Deferred revenue	$ 8,624	$ 55,098
Allowance for doubtful accounts
Inventories, net		$ 12,335
Inventories, reserve	$ 12,335
Measurement of tax benefit, percentage of realized upon settlement, minimum	50.00%
Stock Option [Member]
Antidilutive securities excluded from computation of earnings per share	17,946,667	6,822,500
Warrants [Member]
Antidilutive securities excluded from computation of earnings per share	67,907,728	64,161,304

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Schedule of Company's Consolidated Subsidiaries (Details)	12 Months Ended
	Sep. 30, 2018
State or other jurisdiction of incorporation or organization	Nevada
Psoria-Shield, Inc [Member]
Name of consolidated subsidiary or entity	Psoria-Shield Inc. ("PSI")
State or other jurisdiction of incorporation or organization	The State of Florida
Date of incorporation or formation	Jun. 17, 2009
Date of acquisition/disposition	Aug. 24, 2012
Attributable interest	100.00%
StealthCo, Inc. [Member]
Name of consolidated subsidiary or entity	StealthCo, Inc. ("StealthCo")
State or other jurisdiction of incorporation or organization	The State of Illinois
Date of incorporation or formation	Mar. 18, 2014
Attributable interest	100.00%
Psoria Development Company LLC. [Member]
Name of consolidated subsidiary or entity	Psoria Development Company LLC. ("PDC")
State or other jurisdiction of incorporation or organization	The State of Illinois
Date of incorporation or formation	Jan. 15, 2015
Attributable interest	50.00%

Summary of Significant Accoun_6

Summary of Significant Accounting Policies - Schedule of Estimated Useful Lives of Property and Equipment (Details)	12 Months Ended
	Sep. 30, 2018
Computer Equipment [Member]
Property and equipment, useful life	5 years
Medical Equipment [Member]
Property and equipment, useful life	5 years
Furniture and Fixtures [Member]
Property and equipment, useful life	7 years
Vehicles [Member]
Property and equipment, useful life	3 years
Software [Member]
Property and equipment, useful life	3 years

Discontinued Operations (Detail

Discontinued Operations (Details Narrative) - USD ($)	1 Months Ended	12 Months Ended
	Aug. 11, 2017	Sep. 30, 2018	Sep. 30, 2017
Gain relating to transaction			$ 252,508
Dr. Jay Joshi [Member] | NPC Inc. [Member]
Gain relating to transaction			$ 252,508
Dr. Jay Joshi [Member] | NPC Inc. [Member] | Common Stock [Member]
Number of stock options issued to purchase common stock	500,000
Common stock exercise price	$ 0.25
Fair value of stock options	$ 106,350
NPC Inc. [Member]
Ownership interest, percentage	100.00%
NPC Inc. [Member] | Dr. Jay Joshi [Member]
Ownership interest, percentage	100.00%
Accrued compensation	$ 365,459

Discontinued Operations - State

Discontinued Operations - Statement of Operations of Discontinued Operations (Details) - USD ($)	12 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
Discontinued Operations and Disposal Groups [Abstract]
Total Sales		$ 83,826
Operating expenses		231,302
Loss from discontinued operations		105,032
Gain from sale of discontinued operations		$ 252,508

Property and Equipment (Details

Property and Equipment (Details Narrative) - USD ($)	12 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 2,507	$ 11,125

Property and Equipment - Schedu

Property and Equipment - Schedule of Property and Equipment (Details) - USD ($)	Sep. 30, 2018	Sep. 30, 2017
Property and equipment, gross	$ 106,720	$ 106,720
Less: accumulated depreciation and amortization	(104,101)	(101,594)
Property and equipment, net	2,619	5,126
Vehicles [Member]
Property and equipment, gross	15,000	15,000
Computer Equipment [Member]
Property and equipment, gross	10,456	10,456
Furniture and Fixtures [Member]
Property and equipment, gross	23,998	23,998
Medical Equipment [Member]
Property and equipment, gross	18,889	18,889
Software [Member]
Property and equipment, gross	23,207	23,207
Leasehold Improvements [Member]
Property and equipment, gross	$ 15,170	$ 15,170

Loans Payable from Officers a_2

Loans Payable from Officers and Shareholders (Details Narrative)	12 Months Ended
	Sep. 30, 2018USD ($)$ / sharesshares	Sep. 30, 2017USD ($)Integer	Sep. 30, 2016USD ($)
Loans payable from officers and shareholders	$ 66,000	$ 59,000
Proceeds from short term debt	434,500	50,000
Repayments of short term debt	$ 20,500
Volatility rate, minimum	121.10%	138.20%
Volatility rate, maximum	130.20%	152.30%
Risk-free rates, minimum	2.01%	0.96%
Risk-free rates, maximum	2.85%	1.39%
Fair value of additional shares issued upon conversion of loans payable from officers and shareholders	$ 30,583
Warrant [Member]
Number of warrants issued to purchase shares | shares	3,228,572
Volatility rate, minimum	124.60%
Volatility rate, maximum	124.73%
Risk-free rates, minimum	2.37%
Risk-free rates, maximum	2.43%
Minimum [Member] | Warrant [Member]
Warrant exercise price | $ / shares	$ 0.15
Stock price per share | $ / shares	0.13
Maximum [Member] | Warrant [Member]
Warrant exercise price | $ / shares	0.18
Stock price per share | $ / shares	$ 0.14
22 Short-Term Unsecured Loans [Member]
Proceeds from short term debt	$ 434,500
Debt instrument, payment terms	due one year from the date of issuance
Repayments of short term debt	$ 20,500
Debt instrument conversion value	$ 407,000
Debt instrument conversion shares | shares	2,800,713
Loan Holders [Member]
Number of warrants issued to purchase shares | shares	6,038,336
Warrant expire term	5 years
Fair value of warrants	$ 689,934
Common stock issued during period, shares | shares	218,452
Fair value of additional shares issued upon conversion of loans payable from officers and shareholders	$ 30,583
Loan Holders [Member] | Minimum [Member]
Warrant exercise price | $ / shares	$ 0.14
Loan Holders [Member] | Maximum [Member]
Warrant exercise price | $ / shares	$ 0.18
Unsecured Loans [Member]
Loans payable from officers and shareholders	$ 66,000	$ 59,000	$ 9,000
Debt instrument, payment terms		due on demand
Number of borrowed separate shareholders | Integer		2
Debt instrument, interest rate, stated percentage		0.00%
Unsecured Loans [Member] | Shareholder One [Member]
Proceeds from short term debt		$ 20,000
Unsecured Loans [Member] | Shareholder Two [Member]
Proceeds from short term debt		$ 30,000

Convertible Note Agreements - S

Convertible Note Agreements - Schedule of Convertible Notes Payable (Details) - USD ($)		Sep. 30, 2018	Sep. 30, 2017
Debt discount - unamortized balance		$ (72,078)	$ (115,116)
Convertible note payable, net		202,922	49,884
Convertible Note Payable One [Member]
Convertible note payable	[1]		165,000
Convertible Note Payable Two [Member]
Convertible note payable	[2]	165,000
Convertible Note Payable Three [Member]
Convertible note payable	[3]	$ 110,000
[1]	In July 2017, the Company entered into a Convertible Note Payable Agreement with an individual under which the Company borrowed $165,000. Net proceeds received by the Company under the agreement were $150,000. In connection with the agreement, the Company issued the individual 165,000 restricted shares of its common stock with a fair value of $51,150 and warrants to purchase 330,000 shares of its common stock, which vested upon grant. The warrants expire five years from the date of grant and have an exercise price of $0.50 per share. The note payable accrues interest at eight percent per annum, is unsecured and is convertible at any time after the 90th day from the issue date into the Company's common stock at the fixed conversion price of $0.25 per share. The note matures in February 2018, but may be extended at the option of the individual. The Company may prepay the note at any time immediately following the issue date upon seven days' prior written notice. On the date of the agreement, the closing price of the common stock was $0.31 per share. As the conversion price embedded in the note agreement was below the trading price of the common stock on the date of issuance, a beneficial conversion feature (BCF) was recognized at the date of issuance. The Company recognized a debt discount at the date of issuance in the aggregate amount of $150,000 related to the relative fair value of the warrants and beneficial conversion features, which comprised $94,704 related to the intrinsic value of beneficial conversion features and $55,296 related to the relative fair value of the warrants. The aggregate fair value of the warrants of $87,582 was based on Black-Scholes Merton option pricing model with a stock price of $0.31, volatility of 139.98% and risk-free rate of 1.28%. The unamortized balance of the debt discount at September 30, 2017 was $115,116. The agreement also included a clause that allowed for the individual to receive additional shares if the price of the stock declined as of February 28, 2018 (the maturity date). The price of the stock on that date was $0.12 per share, causing the Company to issue the individual an additional 186,849 shares of its common stock. During the year ended September 30, 2018, the Company recorded a financing cost of $22,422 relating to the issuance of these shares. On March 5, 2018, the Company modified the conversion price on the note payable from $0.25 per share to $0.10 per share. On that date, the reduction in the conversion price allowed for the individual to convert an additional 990,000 shares with a fair value of $0.16 per share. The total amount of expense the Company recognized relating to the modification was $158,400. Also, on March 5, 2018, the Company modified the exercise price on the attached warrants from $0.50 per share to $0.20 per share. The total amount of the cost the Company recognized relating to the modification was $5,445. The maturity date of the note was also extended until April 30, 2018. During the year ended September 30, 2018, the individual converted $165,000 of the convertible note payable and $9,563 of accrued interest into 1,745,631 shares of the Company's common stock. During the year ended September 30, 2018, the Company amortized the remaining $115,116 of debt discount, leaving no unamortized balance at September 30, 2018.
[2]	On March 5, 2018, the Company entered into another Convertible Note Payable Agreement with the same individual under which the Company borrowed an additional $165,000. Net proceeds received by the Company under the agreement after payment of a $15,000 fee to the lender was $150,000. In connection with the agreement, the Company issued the individual 300,000 restricted shares of its common stock with a fair value of $48,000 and warrants to purchase 660,000 shares of its common stock, which vested upon grant. The warrants expire five years from the date of grant and have an exercise price of $0.20 per share. The note payable accrues interest at eight percent per annum, is unsecured and is convertible at any time after the 90th day from the issue date into the Company's common stock at the fixed conversion price of $0.10 per share. The note matures in October 2018, but may be extended at the option of the individual. The Company may prepay the note at any time immediately following the issue date upon seven days' prior written notice. The note is currently past due. The Company calculated the related fair value of the warrants issued to the noteholder to be $55,032 using a Black Scholes Merton option pricing model and performing a relative value calculation. The Company then made a calculation to determine if a beneficial conversion feature (BCF) existed. The beneficial conversion was based upon the effective conversion price based on the proceeds received that were allocated to the convertible instrument. Based upon the Company's calculation, it was determined that a beneficial conversion feature existed amounting to $94,968 and was recorded as a debt discount. As such the Company recognized a debt discount at the date of issuance in the aggregate amount of $165,000 relating to the $15,000 fees paid to the lender, the relative value of the warrants and the BCF. The note discount is being amortized over the term of the note and the unamortized portion is recognized as a reduction to the carrying amount of the Convertible note (a valuation debt discount). During the year ended September 30, 2018, the Company amortized $161,163 of debt discount, leaving an unamortized balance of $3,837 at September 30, 2018. The agreement also included a clause that allowed for the individual to receive additional shares if the price of the stock declined as of September 5, 2018. The price of the stock on that date was $0.13 per share, causing the Company to issue the individual an additional 60,902 shares of its common stock. The Company recorded a financing cost of $7,917 relating to the issuance of these shares. In addition, the Company recorded an additional finance cost of $48,000 related to the fair value of the 300,000 shares of common stock granted at the date issuance.
[3]	On July 11, 2018, the Company entered into another Convertible Note Payable Agreement with the same individual under which the Company borrowed an additional $110,000. Net proceeds received by the Company under the agreement after payment of a $10,000 fee to the lender was $100,000. In connection with the agreement, the Company issued the individual 200,000 restricted shares of its common stock with a fair value of $36,000 and warrants to purchase 440,000 shares of its common stock, which vested upon grant. The warrants expire five years from the date of grant and have an exercise price of $0.18 per share. The note payable accrues interest at eight percent per annum, is unsecured and is convertible at any time after the 90th day from the issue date into the Company's common stock at the fixed conversion price of $0.15 per share. The note matures in February 2019, but may be extended at the option of the individual. The Company may prepay the note at any time immediately following the issue date upon seven days' prior written notice. The Company calculated the related fair value of the warrants issued to the noteholder to be $66,440 using a Black Scholes Merton option pricing model and performing a relative value calculation. The Company then made a calculation to determine if a beneficial conversion feature (BCF) existed. The beneficial conversion was based upon the effective conversion price based on the proceeds received that were allocated to the convertible instrument. Based upon the Company's calculation, it was determined that a beneficial conversion feature existed amounting to $33,560 and was recorded as a debt discount. As such the Company recognized a debt discount at the date of issuance in the aggregate amount of $110,000 relating to the $10,000 fees paid to the lender, the relative value of the warrants and the BCF. The note discount is being amortized over the term of the note and the unamortized portion is recognized as a reduction to the carrying amount of the Convertible note (a valuation debt discount). During the year ended September 30, 2018, the Company amortized $41,759 of debt discount, leaving an unamortized balance of $68,241 at September 30, 2018. In addition, the Company recorded an additional finance cost of $36,000 related to the fair value of the 200,000 shares of common stock granted at the date issuance.

Convertible Note Agreements -_2

Convertible Note Agreements - Schedule of Convertible Notes Payable (Details) (Parenthetical) - USD ($)	Sep. 05, 2018	Jul. 11, 2018	Mar. 05, 2018	Feb. 28, 2018	Jul. 31, 2017	Sep. 30, 2018	Sep. 30, 2017
Proceeds from convertible notes payable						$ 250,000	$ 150,000
Debt instrument, unamortized discount						72,078	115,116
Loss on modification of conversion price on convertible note payable						158,400
Loss on modification of exercise price on warrants in connection with convertible note payable						$ 5,445
Warrant [Member]
Number of warrants issued to purchase shares						3,228,572
Warrant [Member] | Minimum [Member]
Warrant exercise price						$ 0.15
Stock price						0.13
Warrant [Member] | Maximum [Member]
Warrant exercise price						0.18
Stock price						$ 0.14
Convertible Note Payable Agreement One [Member]
Debt instrument, unamortized discount							$ 115,116
Fair value of warrants						$ 87,582
Volatility rate						139.98%
Risk-free rate						1.28%
Conversion of debt into common stock						$ 165,000
Accrued interest						$ 9,563
Conversion of debt into common stock, shares						1,745,631
Amortization of debt discount						$ 115,116
Convertible Note Payable Agreement One [Member] | Warrant [Member]
Stock price						$ 0.31
Convertible Note Payable Agreement One [Member] | Individual [Member]
Debt instrument, face amount					$ 165,000
Proceeds from convertible notes payable					$ 150,000
Number of restricted shares issued					165,000
Restricted shares of common stock at fair value					$ 51,150
Number of warrants issued to purchase shares					330,000
Warrant term					5 years
Warrant exercise price					$ 0.50
Debt instrument interest rate					8.00%
Debt instrument, collateral					unsecured
Debt instrument, convertible, terms of conversion feature					Convertible at any time after the 90th day from the issue date into the Company's common stock at the fixed conversion price of $0.25 per share
Debt instrument conversion price					$ 0.25
Debt instrument maturity date description					February 2,018
Closing price of the common stock					$ 0.31
Debt instrument, unamortized discount					$ 150,000
Intrinsic value of beneficial conversion features					94,704
Fair value of warrants					$ 55,296
Stock price				$ 0.12
Common stock issued, shares				186,849
Stock issuance cost						$ 22,422
Conversion of stock, shares converted			990,000
Stock conversion price			$ 0.16
Loss on modification of conversion price on convertible note payable			$ 158,400
Debt maturity date			Apr. 30, 2018
Convertible Note Payable Agreement One [Member] | Individual [Member] | Minimum [Member]
Debt instrument conversion price			$ 0.10
Convertible Note Payable Agreement One [Member] | Individual [Member] | Maximum [Member]
Debt instrument conversion price			$ 0.25
Convertible Note Payable Agreement One [Member] | Individual [Member] | Warrant [Member]
Loss on modification of exercise price on warrants in connection with convertible note payable			$ 5,445
Convertible Note Payable Agreement One [Member] | Individual [Member] | Warrant [Member] | Minimum [Member]
Debt instrument conversion price			$ 0.20
Convertible Note Payable Agreement One [Member] | Individual [Member] | Warrant [Member] | Maximum [Member]
Debt instrument conversion price			$ 0.50
Convertible Note Payable Agreement Two [Member] | Individual [Member]
Debt instrument, face amount			$ 165,000
Proceeds from convertible notes payable			$ 150,000
Number of restricted shares issued			300,000
Restricted shares of common stock at fair value			$ 48,000
Number of warrants issued to purchase shares			660,000
Warrant term			5 years
Warrant exercise price			$ 0.20
Debt instrument interest rate			8.00%
Debt instrument, collateral			unsecured
Debt instrument, convertible, terms of conversion feature			convertible at any time after the 90th day from the issue date into the Company's common stock at the fixed conversion price of $0.10 per share.
Debt instrument conversion price			$ 0.10
Debt instrument maturity date description			October 2,018
Debt instrument, unamortized discount			$ 94,968			$ 3,837
Fair value of warrants			55,032
Stock price	$ 0.13
Common stock issued, shares	60,902					300,000
Stock issuance cost	$ 7,917					$ 48,000
Amortization of debt discount						161,163
Lender fee			$ 15,000
Convertible Note Payable Agreement Three [Member] | Individual [Member]
Debt instrument, face amount		$ 110,000
Proceeds from convertible notes payable		$ 100,000
Number of restricted shares issued		200,000
Restricted shares of common stock at fair value		$ 36,000
Number of warrants issued to purchase shares		440,000
Warrant term		5 years
Warrant exercise price		$ 0.18
Debt instrument interest rate		8.00%
Debt instrument, collateral		unsecured
Debt instrument, convertible, terms of conversion feature		Convertible at any time after the 90th day from the issue date into the Company’s common stock at the fixed conversion price of $0.15 per share.
Debt instrument conversion price		$ 0.15
Debt instrument maturity date description		February 2,019
Debt instrument, unamortized discount		$ 33,560				$ 68,241
Fair value of warrants		66,440
Common stock issued, shares						200,000
Stock issuance cost						$ 36,000
Amortization of debt discount						$ 41,759
Lender fee		$ 10,000

Shareholders' Equity (Details N

Shareholders' Equity (Details Narrative)	May 15, 2018$ / sharesshares	Jan. 02, 2018shares	Jan. 01, 2018shares	Sep. 30, 2018USD ($)$ / sharesshares	Sep. 30, 2017USD ($)$ / sharesshares	Sep. 30, 2016$ / sharesshares
Common stock, shares authorized				185,000,000	185,000,000	75,000,000
Common stock, par value | $ / shares				$ 0.001	$ 0.001	$ 0.001
Common stock, voting rights						Holders of shares of common stock have full voting rights, one vote for each share held of record.
Common stock, shares issued				100,952,569	90,284,916
Common stock, shares outstanding				100,952,569	90,284,916
Common stock issued for cash | $				$ 177,000	$ 884,600
Number of stock issued for service, amount | $				$ 111,300	$ 138,500
Number of common stock cancel				183,333	5,000
Number options to purchase of common stock			675,000	11,317,500	1,650,000
Options exercisable term		5 years		2 years 11 months 19 days
Options Vesting description			A combined total of 675,000 shares vested in equal amounts over a three-month period, starting on January 1, 2018, with the remainder vesting in equal amounts over the following one year and two months.
Aggregate intrinsic value for warrant shares outstanding | $
Convertible Note Payable [Member]
Number of warrants issued to purchase common shares				1,100,000	330,000
Warrant expiration period				5 years	5 years
Warrant exercise price | $ / shares				$ 0.20	$ 0.31
Officer and Consultants [Member]
Common stock issued for cash | $					$ 1,150,000
Warrant expiration period					5 years
Dr. Jay Joshi [Member] | NPC Inc. [Member]
Number of warrants issued to purchase common shares					500,000
Warrant expiration period					5 years
Warrant exercise price | $ / shares					$ 0.24
Stock based compensation | $					$ 106,350
Officers, Directors and Corporate Employees [Member]
Stock based compensation | $				$ 340,699
Number options to purchase of common stock				8,517,500
Fair value of stock options | $				$ 1,004,450
Options exercisable term				5 years
Stock option exercise price per share | $ / shares				$ 0.14
Unvested compensation | $				$ 663,750
Officers and Shareholders [Member]
Number of warrants issued to purchase common shares				6,038,336
2010 Non-Qualified Stock Option Plan [Member]
Common stock, shares authorized				7,500,000
Settlement Agreement [Member]
Number of stock retired, owned by former owners					250,000
Issuance of shares and warrants, financing cost | $				$ 56,727
Settlement Agreement [Member] | Gain on Extinguishment of Debt [Member]
Liabilities owed to former owners | $					$ 260,027
Equity Agreement [Member]
Number of warrants issued to purchase common shares				1,600,000
Warrant exercise price | $ / shares				$ 0.40
Subscription Agreement [Member]
Sales of price per shares | $ / shares					$ 0.25
Percentage of discount for stock and warrant market price					0.40
Employment Agreement with Four Employees [Member]
Number options to purchase of common stock				2,800,000
Fair value of stock options | $				$ 396,308
Options exercisable term				5 years
Vesting period				3 months
Unvested compensation | $				$ 28,063
Initial Equity Agreement [Member]
Number of warrants issued to purchase common shares				6,104,322
Warrant exercise price | $ / shares				$ 0.18
Maximum [Member]
Number options to purchase of common stock		275,000
Maximum [Member] | Officer and Consultants [Member]
Warrant exercise price | $ / shares					$ 0.40
Maximum [Member] | Officers and Shareholders [Member]
Warrant exercise price | $ / shares				$ 0.18
Maximum [Member] | 2010 Non-Qualified Stock Option Plan [Member]
Common stock, shares authorized				30,000,000
Maximum [Member] | Employment Agreement with Four Employees [Member]
Stock option exercise price per share | $ / shares				$ 0.19
Minimum [Member] | Officer and Consultants [Member]
Warrant exercise price | $ / shares					$ 0.12
Minimum [Member] | Officers and Shareholders [Member]
Warrant exercise price | $ / shares				$ 0.14
Minimum [Member] | 2010 Non-Qualified Stock Option Plan [Member]
Common stock, shares authorized				7,500,000
Minimum [Member] | Employment Agreement with Four Employees [Member]
Stock option exercise price per share | $ / shares				$ 0.10
Common Stock [Member]
Common stock issued for cash | $				$ 1,614	$ 5,837
Common stock issued for cash, shares				1,614,286	5,837,500
Number of warrants issued to purchase common shares					13,715,000
Number of stock issued for service				770,000	450,000
Number of stock issued for service, amount | $				$ 770	$ 450
Number of stock retired, owned by former owners					(250,000)
Common Stock [Member] | November 2018 [Member]
Number of warrants issued to purchase common shares				770,987
Warrant exercise price | $ / shares				$ 0.18
Number of common stock for sale				296,534
Fair value of warrants | $				$ 38,935
Fair value of shares issued | $				$ 17,792
Common Stock [Member] | Equity Agreement [Member]
Number of common stock for sale				333,333	1,600,000
Purchase consideration for sales | $					$ 400,000
Sales of price per shares | $ / shares				$ 0.15	$ 0.25
Common Stock [Member] | Subscription Agreement [Member]
Number of common stock for sale	1,066,667
Number of common stock cancel	1,600,000
Stock Warrants [Member]
Warrant expiration period					5 years
Decrease in warrant exercise price | $ / shares					$ 0.25
Number of warrants exercised to purchase common stock				1,407,619	4,065,414
Warrants to purchase shares of common stock, value | $				$ 170,914	$ 3,000
Stock Warrants [Member] | Maximum [Member]
Warrant exercise price | $ / shares					$ 0.12
Stock Warrants [Member] | Minimum [Member]
Warrant exercise price | $ / shares					$ 0.40
Warrant [Member]
Number of warrants issued to purchase common shares				3,228,572
Warrant expiration period				5 years
Warrant [Member] | Equity Agreement [Member]
Number of warrants issued to purchase common shares				666,667	1,600,000
Warrant exercise price | $ / shares				$ 0.18	$ 0.40
Incremental difference for warrant shares				433,000
Fair value of canceled warrants | $				$ 185,000
Fair value of warrants | $				$ 618,000
Warrant [Member] | Subscription Agreement [Member]
Number of warrants issued to purchase common shares	5,334,334
Warrant exercise price | $ / shares	$ 0.18
Warrant [Member] | Subscription Agreement [Member] | Previously [Member]
Number of warrants issued to purchase common shares	1,600,000
Warrant [Member] | Maximum [Member]
Warrant exercise price | $ / shares				$ 0.18
Warrant [Member] | Minimum [Member]
Warrant exercise price | $ / shares				$ 0.15
Stock Option [Member]
Shares of stock options remaining available for issuance				12,053,333
Stock Option [Member] | Officer and Consultants [Member]
Stock based compensation | $					$ 220,009
Stock Option [Member] | Employment Agreement with Four Employees [Member]
Stock based compensation | $				$ 271,804
Sale of Equity Units [Member]
Number of warrants issued to purchase common shares				3,228,572	13,715,000
Warrant expiration period				5 years	5 years
Sale of Equity Units [Member] | Maximum [Member]
Warrant exercise price | $ / shares				$ 0.18	$ 0.40
Sale of Equity Units [Member] | Minimum [Member]
Warrant exercise price | $ / shares				$ 0.15	$ 0.12

Shareholders' Equity - Schedule

Shareholders' Equity - Schedule of Assumptions Used for Options Granted (Details) - $ / shares	12 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
Expected dividends	0.00%	0.00%
Expected volatility, minimum	121.10%	138.20%
Expected volatility, maximum	130.20%	152.30%
Risk free interest rate, minimum	2.01%	0.96%
Risk free interest rate, maximum	2.85%	1.39%
Expected life of options	2 years 6 months	2 years 6 months
Minimum [Member]
Exercise price	$ 0.10	$ 0.12
Maximum [Member]
Exercise price	$ 0.19	$ 0.40

Shareholders' Equity - Schedu_2

Shareholders' Equity - Schedule of Stock Option Activity (Details) - USD ($)	Jan. 02, 2018	Jan. 01, 2018	Sep. 30, 2018	Sep. 30, 2017
Number of Option Shares Outstanding, Number, Beginning Balance			6,822,500	5,227,500
Number of Option Shares Outstanding, Granted		675,000	11,317,500	1,650,000
Number of Option Shares Outstanding, Cancelled			(183,333)	(5,000)
Number of Option Shares Outstanding, Exercised
Number of Option Shares Outstanding, Expired			(10,000)	(50,000)
Number of Option Shares Outstanding, Number, Ending Balance			17,946,667	6,822,500
Number of Option Shares Outstanding, Vested and exercisable, Ending Balance			11,693,095
Number of Option Shares Outstanding, Unvested, Ending Balance			6,253,572
Weighted Average Exercise Price, Number, Beginning Balance			$ 0.51	$ 0.60
Weighted Average Exercise Price, Granted			0.14	0.21
Weighted Average Exercise Price, Cancelled			0.14	0.09
Weighted Average Exercise Price, Exercised
Weighted Average Exercise Price, Expired			0.75	1
Weighted Average Exercise Price, Number, Ending Balance			0.28	$ 0.51
Weighted Average Exercise Price, Vested and exercisable, Ending Balance			0.36
Weighted Average Exercise Price, Unvested, Ending Balance			$ 0.15
Fair Value at Date of Grant, Number, Beginning Balance			$ 1,865,628	$ 1,539,269
Fair Value at Date of Grant, Granted			1,379,127	326,359
Fair Value at Date of Grant, Cancelled
Fair Value at Date of Grant, Exercised
Fair Value at Date of Grant, Expired
Fair Value at Date of Grant, Number, Ending Balance			3,244,755	$ 1,865,628
Fair Value at Date of Grant, Vested and exercisable, Ending Balance			2,149,818
Fair Value at Date of Grant, Unvested, Ending Balance			$ 1,094,937
Minimum [Member]
Weighted Average Exercise Price, Number, Beginning Balance			$ 0.10	$ 0.01
Weighted Average Exercise Price, Granted			0.10	0.12
Weighted Average Exercise Price, Number, Ending Balance			0.10	0.10
Weighted Average Exercise Price, Vested and exercisable, Ending Balance			0.10
Weighted Average Exercise Price, Unvested, Ending Balance			0.14
Maximum [Member]
Number of Option Shares Outstanding, Granted	275,000
Weighted Average Exercise Price, Number, Beginning Balance			2	2
Weighted Average Exercise Price, Granted			0.19	0.40
Weighted Average Exercise Price, Number, Ending Balance			2	$ 2
Weighted Average Exercise Price, Vested and exercisable, Ending Balance			2
Weighted Average Exercise Price, Unvested, Ending Balance			$ 0.19

Shareholders' Equity - Schedu_3

Shareholders' Equity - Schedule of Outstanding and Exercisable Options by Exercise Price Range (Details) - $ / shares	Jan. 02, 2018	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2016
Range of Exercise Prices, Lower Limit		$ 0.01
Range of Exercise Prices, Upper Limit		$ 2
Number of Options, Outstanding, Number		17,946,667	6,822,500	5,227,500
Number of Options, Outstanding, Weighted Average Remaining Contractual Term		3 years 4 months 28 days
Number of Options, Outstanding, Weighted Average Exercise Price		$ 0.28	$ 0.51	$ 0.60
Number of Options, Exercisable, Number		11,693,095
Number of Options, Exercisable, Weighted Average Remaining Contractual Term	5 years	2 years 11 months 19 days
Number of Options, Exercisable, Weighted Average Exercise Price		$ 0.36
Exercise Price Range One [Member]
Range of Exercise Prices, Lower Limit		0.10
Range of Exercise Prices, Upper Limit		$ 0.39
Number of Options, Outstanding, Number		14,434,167
Number of Options, Outstanding, Weighted Average Remaining Contractual Term		4 years 15 days
Number of Options, Outstanding, Weighted Average Exercise Price		$ 0.15
Number of Options, Exercisable, Number		8,180,595
Number of Options, Exercisable, Weighted Average Remaining Contractual Term		3 years 8 months 16 days
Number of Options, Exercisable, Weighted Average Exercise Price		$ 0.15
Exercise Price Range Two [Member]
Range of Exercise Prices, Lower Limit		0.40
Range of Exercise Prices, Upper Limit		$ 0.99
Number of Options, Outstanding, Number		2,112,500
Number of Options, Outstanding, Weighted Average Remaining Contractual Term		6 months 21 days
Number of Options, Outstanding, Weighted Average Exercise Price		$ 0.40
Number of Options, Exercisable, Number		2,112,500
Number of Options, Exercisable, Weighted Average Remaining Contractual Term		6 months 21 days
Number of Options, Exercisable, Weighted Average Exercise Price		$ 0.40
Exercise Price Range Three [Member]
Range of Exercise Prices, Lower Limit		1
Range of Exercise Prices, Upper Limit		$ 1.99
Number of Options, Outstanding, Number		750,000
Number of Options, Outstanding, Weighted Average Remaining Contractual Term		2 years 2 months 30 days
Number of Options, Outstanding, Weighted Average Exercise Price		$ 1
Number of Options, Exercisable, Number		750,000
Number of Options, Exercisable, Weighted Average Remaining Contractual Term		2 years 2 months 30 days
Number of Options, Exercisable, Weighted Average Exercise Price		$ 1
Exercise Price Range Four [Member]
Range of Exercise Prices, Upper Limit		$ 2
Number of Options, Outstanding, Number		650,000
Number of Options, Outstanding, Weighted Average Remaining Contractual Term		2 years 2 months 30 days
Number of Options, Outstanding, Weighted Average Exercise Price		$ 2
Number of Options, Exercisable, Number		650,000
Number of Options, Exercisable, Weighted Average Remaining Contractual Term		2 years 2 months 30 days
Number of Options, Exercisable, Weighted Average Exercise Price		$ 2

Shareholders' Equity - Schedu_4

Shareholders' Equity - Schedule of Warrant Activity (Details) - Warrant [Member] - USD ($)	12 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
Number of Warrant Shares Outstanding, Number, Beginning Balance	64,161,304	54,938,158
Number of Warrant Shares Outstanding, Granted	16,471,230	14,045,000
Number of Warrant Shares Outstanding, Cancelled	(1,600,000)
Number of Warrant Shares Outstanding, Exercised	(1,407,619)	(4,065,414)
Number of Warrant Shares Outstanding, Expired	(9,717,187)	(756,440)
Number of Warrant Shares Outstanding, Number, Ending Balance	67,907,728	64,161,304
Number of Warrant Shares Outstanding, Vested and exercisable, Ending Balance	67,907,728
Number of Warrant Shares Outstanding, Unvested, Ending Balance
Weighted Average Exercise Price, Number, Beginning Balance	$ 0.24	$ 0.25
Weighted Average Exercise Price, Granted	0.17	0.19
Weighted Average Exercise Price, Cancelled	0.40
Weighted Average Exercise Price, Exercised	0.12	0.15
Weighted Average Exercise Price, Expired	0.56	0.86
Weighted Average Exercise Price, Number, Ending Balance	0.17	$ 0.24
Weighted Average Exercise Price, Vested and exercisable, Ending Balance	0.17
Weighted Average Exercise Price, Unvested, Ending Balance
Fair Value at Date of Issuance, Number, Beginning Balance	$ 2,151,219	$ 2,063,637
Fair Value at Date of Issuance, Granted	1,283,341	87,582
Fair Value at Date of Issuance, Cancelled
Fair Value at Date of Issuance, Exercised
Fair Value at Date of Issuance, Expired
Fair Value at Date of Issuance, Number, Ending Balance	3,434,560	$ 2,151,219
Fair Value at Date of Issuance, Vested and exercisable, Ending Balance	3,434,560
Fair Value at Date of Issuance, Unvested, Ending Balance
Minimum [Member]
Weighted Average Exercise Price, Number, Beginning Balance	$ 0.12	$ 0.01
Weighted Average Exercise Price, Granted	0.14	0.12
Weighted Average Exercise Price, Exercised	0.12	0.12
Weighted Average Exercise Price, Expired	0.30	0.45
Weighted Average Exercise Price, Number, Ending Balance	0.12	0.12
Weighted Average Exercise Price, Vested and exercisable, Ending Balance	0.12
Maximum [Member]
Weighted Average Exercise Price, Number, Beginning Balance	1	2.31
Weighted Average Exercise Price, Granted	0.20	0.40
Weighted Average Exercise Price, Exercised	0.15	0.25
Weighted Average Exercise Price, Expired	2.31	2.31
Weighted Average Exercise Price, Number, Ending Balance	1	$ 1
Weighted Average Exercise Price, Vested and exercisable, Ending Balance	$ 1

Shareholders' Equity - Schedu_5

Shareholders' Equity - Schedule of Outstanding and Exercisable Warrants by Exercise Price Range (Details) - $ / shares	12 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2016
Range of Exercise Prices, Lower Limit	$ 0.01
Range of Exercise Prices, Upper Limit	2
Exercise Price Range One [Member]
Range of Exercise Prices, Lower Limit	0.10
Range of Exercise Prices, Upper Limit	0.39
Exercise Price Range Two [Member]
Range of Exercise Prices, Lower Limit	0.40
Range of Exercise Prices, Upper Limit	0.99
Exercise Price Range Three [Member]
Range of Exercise Prices, Lower Limit	1
Range of Exercise Prices, Upper Limit	1.99
Warrant [Member]
Range of Exercise Prices, Lower Limit	0.12
Range of Exercise Prices, Upper Limit	$ 1
Number of Warrants, Outstanding, Number	67,907,728	64,161,304	54,938,158
Number of Warrants, Outstanding, Weighted Average Remaining Contractual Term	2 years 10 months 14 days
Number of Warrants, Outstanding, Weighted Average Exercise Price	$ 0.17
Number of Warrants, Exercisable, Number	67,907,728
Number of Warrants, Exercisable, Weighted Average Remaining Contractual Term	2 years 10 months 14 days
Number of Warrants, Exercisable, Weighted Average Exercise Price	$ 0.17
Warrant [Member] | Exercise Price Range One [Member]
Range of Exercise Prices, Lower Limit	0.12
Range of Exercise Prices, Upper Limit	$ 0.20
Number of Warrants, Outstanding, Number	58,994,670
Number of Warrants, Outstanding, Weighted Average Remaining Contractual Term	3 years 15 days
Number of Warrants, Outstanding, Weighted Average Exercise Price	$ 0.15
Number of Warrants, Exercisable, Number	58,994,670
Number of Warrants, Exercisable, Weighted Average Remaining Contractual Term	3 years 15 days
Number of Warrants, Exercisable, Weighted Average Exercise Price	$ 0.15
Warrant [Member] | Exercise Price Range Two [Member]
Range of Exercise Prices, Lower Limit	0.21
Range of Exercise Prices, Upper Limit	$ 0.49
Number of Warrants, Outstanding, Number	8,574,570
Number of Warrants, Outstanding, Weighted Average Remaining Contractual Term	1 year 9 months 11 days
Number of Warrants, Outstanding, Weighted Average Exercise Price	$ 0.28
Number of Warrants, Exercisable, Number	8,574,570
Number of Warrants, Exercisable, Weighted Average Remaining Contractual Term	1 year 9 months 11 days
Number of Warrants, Exercisable, Weighted Average Exercise Price	$ 0.28
Warrant [Member] | Exercise Price Range Three [Member]
Range of Exercise Prices, Lower Limit	0.50
Range of Exercise Prices, Upper Limit	$ 1
Number of Warrants, Outstanding, Number	338,488
Number of Warrants, Outstanding, Weighted Average Remaining Contractual Term	9 months 11 days
Number of Warrants, Outstanding, Weighted Average Exercise Price	$ 0.68
Number of Warrants, Exercisable, Number	338,488
Number of Warrants, Exercisable, Weighted Average Remaining Contractual Term	9 months 11 days
Number of Warrants, Exercisable, Weighted Average Exercise Price	$ 0.68

Settlement of Accrued Liabili_2

Settlement of Accrued Liabilities Acquired with PSI Acquisition (Details) - USD ($)	12 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
Gain on settlement of aggregate amount		$ 288,777
Settlement Agreement [Member]
Acquisition of interest in common shares	250,000
Advances owed to related party	$ 224,444
Settlement Agreement [Member] | Edwin Longo [Member]
Advances owed to related party		224,444
Notes payable		64,333
Gain on settlement of aggregate amount		$ 288,777
Psoria-Shield, Inc [Member]
Advance settlement of prior acquisition	$ 224,444

Segment Reporting - Schedule of

Segment Reporting - Schedule of Assets of Reportable Segments (Details) - USD ($)	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2016
Cash	$ 4,210	$ 29,369	$ 81,749
Prepaid expenses and other current assets	1,550	1,751
Total current assets	5,760	68,454
Property and equipment, net	2,619	5,126
Other assets	16,760	16,760
Total other assets	19,379	21,886
TOTAL ASSETS	25,139	$ 90,340
Corporate [Member]
Cash	331
Prepaid expenses and other current assets
Total current assets	331
Property and equipment, net
Other assets	15,000
Total other assets	15,000
TOTAL ASSETS	15,331
Medical Devices [Member]
Cash	1,452
Prepaid expenses and other current assets
Total current assets	1,452
Property and equipment, net
Other assets	1,760
Total other assets	1,760
TOTAL ASSETS	3,212
Authentication and Encryption [Member]
Cash	2,427
Prepaid expenses and other current assets	1,550
Total current assets	3,977
Property and equipment, net	2,619
Other assets
Total other assets	2,619
TOTAL ASSETS	$ 6,596

Segment Reporting - Schedule _2

Segment Reporting - Schedule of Operations of Reportable Segments (Details) - USD ($)	12 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
Total Sales	$ 213,723	$ 272,724
Cost of goods sold	79,960	146,944
Gross profit	133,763	125,780
Operating expenses	2,226,362	2,129,184
Loss from operations	(2,092,599)	(2,003,404)
Trade [Member]
Total Sales	140,023	209,599
Consulting Services [Member]
Total Sales	73,700	63,125
Corporate [Member]
Total Sales
Cost of goods sold
Gross profit
Operating expenses	1,179,937	1,066,227
Loss from operations	(1,179,937)	(1,066,227)
Corporate [Member] | Trade [Member]
Total Sales
Corporate [Member] | Consulting Services [Member]
Total Sales
Medical Devices [Member]
Total Sales	45,000	180,999
Cost of goods sold		71,827
Gross profit	45,000	109,172
Operating expenses	224,196	436,557
Loss from operations	(179,196)	(327,385)
Medical Devices [Member] | Trade [Member]
Total Sales	45,000	180,999
Medical Devices [Member] | Consulting Services [Member]
Total Sales
Authentication and Encryption [Member]
Total Sales	168,723	91,725
Cost of goods sold	79,960	75,117
Gross profit	88,763	16,608
Operating expenses	822,229	626,400
Loss from operations	(733,466)	(609,792)
Authentication and Encryption [Member] | Trade [Member]
Total Sales	95,023	28,600
Authentication and Encryption [Member] | Consulting Services [Member]
Total Sales	$ 73,700	$ 63,125

Commitments (Details Narrative)

Commitments (Details Narrative) - USD ($)	12 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Apr. 13, 2018
Lease expiration date	Feb. 28, 2024
Deferred rent obligation	$ 130,260	$ 85,294
Payments for Rent	188,801	$ 183,685
CEO [Member]
Total payments to employee	$ 450,000
Trading expense			$ 130,000
Lease Agreement [Member]
Lease expiration date	Sep. 30, 2021
Employment Agreement with One Employee [Member]
Accumulated base salary	$ 350,000
Employment Agreement with Two Employees [Member]
Accumulated base salary	350,000
Employment Agreement with Three Employees [Member]
Accumulated base salary	350,000
Employment Agreement with Four Employees [Member]
Accumulated base salary	$ 350,000

Commitments - Summary of Minimu

Commitments - Summary of Minimum Annual Rental Commitments Under Non-cancelable Leases (Details)	Sep. 30, 2018USD ($)
Commitments and Contingencies Disclosure [Abstract]
2,019	$ 145,812
2,020	164,614
2,021	184,583
2,022	152,709
2,023	158,527
Thereafter	67,871
Total	$ 874,116

Income Taxes (Details Narrative

Income Taxes (Details Narrative)	12 Months Ended
	Sep. 30, 2018USD ($)
Income Tax Disclosure [Abstract]
Net operating loss carryforwards for federal income tax	$ 16,000,000
Net operating loss carryforwards expire year	Future taxable income through 2038
Deferred tax carryforwards offset by valuation allowance	$ 6,000,000

Income Taxes - Schedule of Effe

Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)	12 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
Income Tax Disclosure [Abstract]
Income tax benefit at federal statutory rate	(21.00%)	(34.00%)
State income tax benefit, net of federal benefit	(4.00%)	(6.00%)
Change in valuation allowance	25.00%	40.00%
Income taxes at effective income tax rate	0.00%	0.00%

Income Taxes - Schedule of Defe

Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details) - USD ($)	Sep. 30, 2018	Sep. 30, 2017
Income Tax Disclosure [Abstract]
Net operating loss carryforwards	$ 5,884,083	$ 5,535,673
Less: Valuation allowance	(5,884,083)	(5,535,673)
Net deferred tax assets

Related Party Transactions (Det

Related Party Transactions (Details Narrative) - USD ($)	Jan. 02, 2018	Jan. 01, 2018	Sep. 30, 2018	Sep. 30, 2017
Stock options to purchase a common stock granted		675,000	11,317,500	1,650,000
Stock option granted exercise price per shares			$ 0.14	$ 0.21
Shares based compensation exercisable term	5 years		2 years 11 months 19 days
Andrew J. Kandalepas [Member]
Officers compensation			$ 182,375	$ 250,000
Stock options to purchase a common stock granted			1,300,000
Stock option granted exercise price per shares			$ 0.14
Shares based compensation exercisable term			5 years
Accrued compensation			$ 81,965	$ 13,440

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - USD ($)	Nov. 15, 2018	Sep. 30, 2018
January 31, 2019 [Member]
Contributed capital		$ 700,000
Subsequent Event [Member]
Repayment of investments	$ 700,000
Distributable cash	$ 300,000
Subsequent Event [Member] | Psoria-Shield, Inc [Member]
Ownership percentage	58.50%
Subsequent Event [Member] | Gen 2 Funding, Inc [Member]
Ownership percentage	28.00%
Subsequent Event [Member] | Neo Phototherapy LLC [Member]
Additional units reserved for issuance	13.50%